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ABSTRACT 
The use of exogenous triggers of RNAi such as short hairpin RNAs (shRNAs) in 
combination with viral vector-mediated gene delivery holds great potential for 
applications in gene therapy, in biotechnological processes as well as in basic 
research. Ideally, shRNAs only exert their activity via the antisense strand that 
binds and silences the designated target mRNA. However, the undesired sense 
strand can also be activated and hence holds a certain silencing potential. In 
principle, this may contribute to erratic off‐targeting which typically occurs via 
imperfect binding and subsequent inhibition of untargeted cellular mRNAs. The 
aim of this study was to assess whether shRNA sense strand activity plays an 
important role in producing off-target effects and –if so- to find novel means of 
counteracting this activity. 
Functional characterization of relative strand activities of different shRNAs indeed 
revealed high levels of undesired sense strands activity for most RNAi triggers. 
This effect was found both upon plasmid transfection and rAAV2-mediated 
transduction which represents a therapeutically relevant system for gene delivery. 
We therefore devised a novel strategy for sense strand counteraction in which an 
shRNA is co‐expressed with an inhibitor RNA transcript designed to stably 
sequester and inactivate the sense but not the antisense strand. Proof‐of‐concept 
for our approach was obtained in transfected human cells with an shRNA against 
hepatitis C virus (HCV). By using RNA-polymerase III-transcribed inhibitors 
known as tough decoys (TuDs) we could efficiently and specifically counteract 
the sense strand of the HCV-shRNA in luciferase and eGFP-based reporter 
assays. We then tested the shRNA-TuD combination in the context of a single 
self-complementary rAAV2 vector. TuD co-expression led to impairment of sense 
strand activity upon transduction of HEK293T and Huh7 cells. Inhibition of HCV 
replication in Huh7 cells was not altered indicating that the desired antisense 
strand activity was unaffected. Our strategy is hence compatible with rAAV-
mediated gene delivery. Furthermore, expression profiling in Huh7 cells revealed 
that TuD co-expression specifically de-repressed endogenous off-target 
transcripts that carried seed matches to the shRNA sense strand leading to lower 
levels of perturbation of global gene expression. As expected, repression of 
transcripts carrying antisense strand seed matches remained unaffected. These 
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results show that shRNA sense strands can indeed contribute to off-targeting and 
that TuD-mediated inhibition can be used to counteract this effect.   
Besides our functional data, we also defined rules for TuD and shRNA design as 
well as promoter choice which allows implementation of the system for other 
shRNAs.  
In this study, we provide new insights into the functionalities and relative activities 
of both strands of shRNAs. We furthermore present TuD-mediated selective 
counteraction of shRNA sense strands as a novel method to improve the 
functional strand bias and thus increase shRNA specificity. We are optimistic that 
our strategy will facilitate and further foster the clinical implementation of vector-
based RNAi. 
                 ZUSAMMENFASSUNG 
______________________________________________________________________________ 
ZUSAMMENFASSUNG 
Die Kombination aus exogenen RNAi auslösenden Molekülen wie z.B. short 
hairpin RNAs (shRNAs) und Gentransfer durch virale Vektoren hat ein enormes 
Potenzial für Anwendungen in der Gentherapie, in biotechnologischen Prozessen 
sowie in der Grundlagenforschung. Idealerweise sollte die Aktivität von shRNAs 
nur durch den antisense Strang ausgeführt werden, welcher das erwünschte 
zelluläre Ziel bindet und inhibiert. Prinzipiell kann jedoch auch dem 
unerwünschten sense Strang eine gewisse Inhibierungsaktivität innewohnen. 
Dies kann zu unerwünschten off-target Effekten von shRNAs beitragen, welche 
normalerweise durch imperfekte Bindung und anschließende Inhibierung von 
nicht anvisierten zellulären mRNAs auftreten. Die vorliegende Studie sollte 
zunächst herausfinden, ob shRNA sense Strang Aktivität zu nennenswerten off-
target Effekten führen kann. Falls zutreffend, sollten desweiteren neue Ansätze 
entwickelt werden, um diese Aktivität zu verringern. 
Die funktionale Charakterisierung der relativen Strangaktivität verschiedener 
shRNAs offenbarte, dass die sense Stränge in den meisten Fällen tatsächlich 
eine hohe Aktivität aufweisen. Dies wurde sowohl nach Plasmidtransfektion als 
auch nach Transduktion durch AAV Vektoren, welche ein relevantes System für 
den therapeutischen Gentransfer darstellen, beobachtet. Aus diesem Grund 
entwickelten wir eine neue Strategie, in der shRNAs gemeinsam mit einer 
Inhibitor-RNA exprimiert werden, welche den unerwünschten sense-Strang, nicht 
jedoch den erwünschten antisense Strand der shRNA dauerhaft bindet und 
inaktiviert. Unser Ansatz wurde in transfizierten humanen Zellen mit einer vorher 
beschriebenen shRNA gegen Hepatitis C Virus (HCV) getestet. Mit Hilfe von 
RNA-Polymerase III-transkribierten Inhibitor Molekülen, die als tough decoys 
(TuDs) bekannt sind, konnten der sense Strang Aktivität der HCV shRNA effizient 
entgegengewirkt werden. Als nächstes wurde die Kombination aus shRNA und 
TuD im Kontext von selbst-komplementären rAAV2 Vektoren getestet. Wir 
konnten beobachten, dass Ko-Expression des TuDs nach Transduktion von 
HEK293T und Huh7 Zellen zu einer starken Beeinträchtigung der sense Strang 
Aktivität führte. Die Inhibition der HCV Replikation in Huh7 Zellen war jedoch 
unverändert, was auf einer unveränderte Aktivität des erwünschten antisense 
Stranges schließen lässt. Dies bedeutet, dass unsere Strategie mit dem 
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Gentranfer durch AAV Vektoren kompatibel ist. Eine Analyse der Genexpression 
in Huh7 Zellen offenbarte desweiteren, dass durch die Ko-expression des TuD 
endogene off-target Transkripte, welche komplemetäre Sequenzen zur seed 
Sequenz des shRNA sense Stranges trugen, spezifisch de-reprimiert wurden. 
Dies hatte auch eine geringere globale Deregulierung der Genexpression durch 
die shRNA zur Folge. Wie erwartet war die Repression von Transkripten mit 
komplementären Sequenzen zur seed Sequenz des antisense Stranges 
unverändert. Diese Ergebnisse verdeutlichen, dass der sense Strang von 
shRNAs tatsächlich zu off-target Effekten beitragen und dass diesen durch Ko-
Expression von TuDs entgegengewirkt werden kann. 
Zusätzlich zu den funktionalen Daten wurden Richtlinien für das Design von 
shRNA und TuD sowie für die Wahl des Promotors bestimmt, wodurch eine 
Übertragung des Systems auf andere shRNAs ermöglicht wird.  
Diese Studie liefert neue Einblicke in die Funktionalität und die relativen 
Aktivitäten beider Stränge von shRNAs. Desweiteren wird die selektive Inhibition 
von shRNA sense Strängen durch TuDs als neue Methode zur Erhöhung von 
shRNA Spezifitäten vorgestellt. Diese Methode könnte zur zukünftigen klinischen 
Einführung von vektorbasierten RNAi Therapien beitragen. 
                                                                                                         INTRODUCTION 
______________________________________________________________________________  
 
1 INTRODUCTION 
RNA interference (RNAi) is a cellular mechanism for post-transcriptional silencing 
of specific genes that can be found in a wide variety of eukaryotic organisms. It 
requires an endogenous or exogenous double-stranded small RNA molecule that 
interacts with, and subsequently inhibits a target mRNA. On the one hand, the 
discovery of the endogenous RNAi machinery has vastly improved our 
knowledge about cellular regulation of gene expression with important 
implications for human disease phenotypes. On the other hand, the application of 
exogenous triggers of RNAi has proven to be a highly versatile, potent and, 
importantly, easy-to-use gene silencing tool and has already started to 
revolutionize basic science as well as biomedical research and biotechnological 
applications. Another molecular state-of-the-art technology is the use of viral 
vectors for highly potent and to some degree specific delivery of genetic material 
to target cells. This approach exploits the natural ability of different viruses to 
infect cells and then unpack their genetic material for potent expression, and has 
been successfully applied in a wide variety of settings ranging from basic tissue 
culture experiments to more elaborate applications like gene therapy. Although 
first used in the early 70s, viral vector technology has only revealed its true 
potential within the past ten years culminating in its recent use in a range of 
clinical trials in different gene therapeutic applications. The combination of viral 
vectors and RNAi is thus a highly promising approach for the treatment of 
different human pathologies ranging from central nervous system (CNS) 
disorders over cancer to infectious diseases. While it has already shown a 
number of exciting results in the past years its use in gene therapy still requires 
further characterization and optimization. In this study, we aimed at improving 
current approaches for specific gene silencing in potentially gene therapeutic 
settings using viral vectors and RNAi. 
 
1.1 RNA interference 
1.1.1 History of RNA interference 
The first report on what later would be identified as a completely novel class of 
conserved regulatory RNA molecules was published by the Ambros lab in 1993 
(Lee et al., 1993). The group described the gene product of the lin-4 gene in 
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Caenorhabditis elegans (C.elegans) as two non-protein-coding RNAs of 22 
nucleotides (nt) and 61nt in length that were able to negatively regulate 
expression of the lin-14 gene which carried sequence similarities to lin-4. After 
this initial discovery it was not until 1998 that a major breakthrough would lead to 
a huge leap forward in the field. A groundbreaking publication by Andrew Fire 
and Craig Mello described for the first time the targeted inhibition of expression of 
specific genes by exogenous double-stranded RNA (dsRNA) molecules with 
perfect complementarity to a target mRNA (Fire et al., 1998). The phenomenon 
was termed RNA interference (RNAi). Later a link between the previous findings 
of the Ambros lab and RNAi was discovered as it turned out that the lin-4 gene 
products were in fact endogenous counterparts to the exogenous dsRNAs used 
by Fire and Mello (Ambros, 2001). Curiously, the description of exogenous RNAi 
preceded the discovery of the endogenous machinery turning the classical 
scenario where a biological discovery leads to a technological breakthrough 
upside down. When a second non-coding RNA molecule was discovered in the 
year 2000 that had characteristics similar to lin-4 and that was widely conserved 
across species the term microRNA (miRNA) was coined for such small regulatory 
RNA molecules (Reinhart et al., 2000; Pasquellini et al., 2000; Lee and Ambros, 
2001). While investigations on miRNAs soon became a discipline in molecular 
biology in its own right the more technological finding of exogenously induced 
RNAi started a revolution in modern molecular biology. After the initial discovery 
in C.elegans by Fire and Mello the same principles were found to be active in 
Drosophila melanogaster and shortly thereafter also in mammalian and most 
importantly in human cells (Kennerdell and Carthew, 1998; Caplen et al., 2001; 
Elbashir et al., 2001a). Nowadays we know that the principle of RNAi is highly 
conserved across eukaryotes and is thus believed to have arisen early in 
evolution (Cerutti and Casas-Mollano, 2006). The possibility to adapt the system 
to virtually any RNA sequence rapidly led to novel concepts in functional 
genomics and new strategies for the treatment of a wide range of both genetic 
and infectious diseases (Grimm and Kay, 2007a; Tiemann and Rossi, 2009). 
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1.1.2 Gene silencing by endogenous triggers of RNAi- the human miRNA 
pathway 
The small RNA components of the RNAi machinery generally act as homing 
devices that sequence-specifically recruit effector proteins to cellular target RNAs 
which leads to their translational inhibition and/or degradation (for review see 
Fabian et al., 2010). The major class of such homing RNAs in humans as well as 
in other species are miRNAs that are single-stranded 21-24nt long RNAs in their 
mature form. The canonical endogenous miRNA pathway starts with the nuclear 
synthesis of a primary transcript that is termed pri-miRNA mostly by RNA-
polymerase II (RNA-pol II) (Lee et al., 2002; Lee et al., 2004; Fig. 1). A hairpin 
structure within these molecules is recognized by the endonuclease Drosha that 
in concert with DGCR8 is termed microprocessor and excises a hairpin-shaped 
precursor molecule named pre-miRNA (Lee et al., 2003; Han et al., 2004). These 
small hairpin precursors are subsequently bound by Exportin-5 and transported 
into the cytoplasm (Yi et al., 2003; Zeng and Cullen, 2004). The preceding 
Drosha processing leaves a short overhang at the 3’ end of the pre-miRNA which 
is recognized by another cytoplasmic endonuclease called Dicer that cuts 22nt 
upstream of the 3’ end in an asymmetric fashion. This leads to the removal of the 
hairpin loop and a duplex RNA molecule with 3’ overhangs at either end 
(Bernstein et al., 2001; Provost et al., 2002). Dicer and its co-factor TRBP then 
transfer the duplex into the RNA-induced silencing complex (RISC) whose main 
components are Argonaute (Ago) RNA binding proteins and associated TNRC6 
proteins along with other factors required for downstream gene silencing 
processes (Chendrimada et al., 2005; Landthaler et al., 2008). In humans there 
exist four different Ago proteins (Ago1-4) and three different TNRC6 proteins 
(TNRC6A-C) whose functions seem largely redundant (Su et al., 2009; Lazzaretti 
et al., 2009; Zipprich et al., 2009). After loading of the RNA duplex, one of the two 
strands is removed leaving the activated RISC which is ready to bind and silence 
RNAs that carry sequences partially or fully complementary to the loaded strand 
(Matranga et al., 2005; Rand et al., 2005). The strand that is finally guiding RISC 
to its targets is called “guide strand” and the discarded strand “passenger strand”. 
RISC binding to target RNAs leads to two different outcomes depending on the 
nature of the miRNA binding site. In case of perfect complementarity to the guide 
strand the target may be directly cleaved and thus inactivated in a fast and 
14 
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efficient way (Martinez et al., 2002; see next section). Imperfect complementarity 
leads to translational inhibition as well as accelerated decay without direct 
cleavage (Valencia-Sanchez et al., 2006). In case of such target RNAs that are 
not cleaved RISC recruits downstream factors such as the Ccr4-Not1 
deadenylase complex and decapping factors like Dcp1 and Dcp2 that are part of 
the 5’?3’ RNA degradation machinery (Behm-Ansmant et al., 2006). The target 
RNAs are subsequently concentrated in cytoplasmic foci called processing 
bodies (P-bodies) which appear to be the sites of degradation (Parker and Sheth, 
2007). 
1.1.3 Perfect and imperfect targets and hAgo2 slicing activity 
The exact sequence features that render a specific RNA susceptible to miRNA 
binding and subsequent silencing are still not fully understood (Bartel, 2009). This 
is because basically all identified endogenous targets for miRNAs do not show 
perfect complementarity to the respective miRNA (Lai, 2002). Instead, partial 
complementarity was found to be sufficient. Due to the low stringency of target 
recognition one single miRNA can potentially have hundreds of different targets 
(Lim et al., 2005). A key finding in the search for parameters that are important 
for miRNA-target binding was the notion that sequence stretches with perfect 
complementarity to the first eight 5’ nucleotides -with particular importance of 
nucleotide 2-8- of the miRNA are sufficient for mRNA binding and repression 
(Doench and Sharp, 2004). This suggests that the binding reaction between 
miRNA and target commences at the miRNA 5’ end where the complementarity 
hence has to be rather optimal and then proceeds with less stringent 
requirements towards the 3’ end. These essential 5’ nucleotides within the 
miRNA strand were therefore termed “seed” region (Lewis et al., 2005). However, 
it is important to note that i) the seed match rule is not exclusive as other binding 
modes have been proposed that, for example, require nucleotides matching the 
center of the miRNA or imperfect seed matches (Shin et al., 2010; Chi et al., 
2012) and ii) the mere presence of a seed match does not guarantee that the 
corresponding mRNA is a real target (Didiano and Hobert, 2006). The latter is 
linked to the fact that unrelated sequence features flanking the seed match may 
dramatically alter the likelihood of the sequence to be bound (Kertesz et al., 
2007). Since these flanking features are difficult to take into account miRNA 
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target prediction is still far from being perfect. Nevertheless, seed matching is 
currently the best described binding mode and holds true for the majority of 
validated miRNA targets. It is also noteworthy that most miRNA binding sites 
have been found in the 3’ UTRs of their target genes (Lai, 2002; Bartel, 2009). 
The biological reason for this appears to be that when RISC binds to targets in 
the 5’ UTR or the open reading frame (ORF) it can be stripped off the transcript 
by polysomes (Gu et al., 2009). In addition, 5’ UTRs are also usually much 
shorter than 3’ UTRs and therefore have a lower capacity for regulatory 
sequences (Mazumder et al., 2003). However, it has been shown that binding 
sites in the 5’ UTR and the coding sequence can also be functional (Lytle et al., 
2007; Hafner et al., 2010; Reczko et al., 2012). 
Although imperfect binding sites represent the vast majority of known 
endogenous miRNA targets, the effect on perfect target sites as used initially by 
Mello and Fire in their application of exogenous triggers of RNAi is dramatically 
more potent. This phenomenon could be linked to a catalytic activity of some but 
not all members of the Ago family that cleave -or “slice”- target RNAs with perfect 
or nearly perfect complementarity to the bound guide strand, an attribute that is 
called “slicer activity” (Liu et al., 2004; Meister et al., 2004). In humans, only 
hAgo2 is able to slice whereas hAgo1, 3 and 4 exclusively act via accelerated 
decay and translational inhibition, regardless of the nature of the binding site (Su 
et al., 2009). In addition to target slicing, the catalytic activity of hAgo2 has 
recently been linked to RISC activation with perfectly complementary RNA 
duplexes (Matranga et al., 2005; Diederichs and Haber, 2007; Gu et al., 2011). 
By slicing the passenger strand hAgo2 is able to destabilize the duplex so that 
the passenger strand can be efficiently removed. In contrast, the other human 
Agos remain bound to the duplex and are unable to direct target silencing if the 
thermodynamic stability of the molecule is too high. This effect is most 
pronounced with hairpin-derived RNAi triggers but not with siRNAs that mimic the 
Dicer processing product (Gu et al., 2011). However, most but not all 
endogenous miRNAs do not have perfectly complementary stems and are thus 
readily activated in all four hAgos. One example for a particular miRNA with 
perfect stem is miR-451 whose final maturation and activation are uncoupled 
from the canonical miRNA pathway and depend solely on hAgo2 slicing activity 
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(Cheloufi et al., 2010; Cifuentes et al., 2010; Yang et al., 2010a). Dicer which 
usually trims the miRNA precursor is not required in this process. 
1.1.4 Gene silencing by exogenous triggers of RNAi – siRNAs and shRNAs 
Aside from endogenous triggers of RNAi there are also different classes of 
exogenous counterparts that make use of the underlying molecular mechanisms 
for targeted silencing of specific genes (Fig. 1). All of these classes have in 
common that they are typically designed to have perfect complementarity to the 
designated target RNA in order to allow slicing to occur and thereby maximize the 
silencing effect. The first and still most famous molecules are exogenous small 
interfering RNAs (siRNAs) that were found to be potent inhibitors of gene 
expression in initial studies (Elbashir et al., 2001b). siRNAs consist of two 
complementary 21nt long RNA strands that hybridize to form a 19-mer duplex 
with 2nt 3’ overhangs at either side. They hence structurally resemble mature 
miRNA duplexes after Dicer processing and can be directly incorporated into 
RISC. While usually yielding potent silencing of target genes, siRNAs are 
expensive and only permit transient effects on gene expression as they are 
degraded in the cell with time (Czauderna et al., 2003). However, for some 
applications -e.g. in gene therapy or long-term silencing experiments- it is 
necessary to generate more sustained RNAi responses. Thus, strategies were 
devised that did not require transfection of chemically synthesized siRNAs but, 
instead, were based on the production of the RNAi trigger within the target cell. 
To this end, RNA-polymerase III (RNA-pol III) promoters were used in an initial 
attempt to transcribe a defined DNA sequence from either side to obtain 
complementary RNAs that could form a duplex and provoke an RNAi response. 
However, although functional to a certain degree this strategy was rather 
inefficient (Miyagishi and Taira, 2002; Jin et al., 2011). Hence, the stem-loop 
structure of miRNA precursors was copied so that instead of two separate 
strands one single precursor molecule was produced that carried the two 
complementary strands connected by a short loop sequence. Due to their 
structure these molecules were termed short hairpin RNAs (shRNAs). This 
approach yielded highly potent and sustained gene silencing and thus paved the 
way for a broad application in human functional genomics and potential gene 
therapeutic strategies (McManus et al., 2002; Paddison et al., 2002; Yu et al., 
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2002; Zeng et al., 2002). Ever since their initial description, shRNAs have been 
steadily modified and improved so that we now have a wide variety of different 
options at hand. Besides the “classical” RNA-pol III-driven shRNAs with perfectly 
complementary stems, shRNAs can also be designed to carry mismatches in 
their stems and to be transcribed by RNA-pol II promoters. Each of these 
strategies has advantages and drawbacks. RNA-pol III promoters, for instance, 
allow transcription of a precise precursor molecule that bypasses Drosha 
processing and yields high levels of mature shRNA strands but these promoters 
do not permit facile tissue-specific expression. The latter can only be envisioned 
with engineered inducible RNA-pol III promoter where a transcriptional activator 
is expressed from a tissue-specific RNA-pol II promoter (Gupta et al., 2004). 
While tissue-specificity is much easier to obtain with RNA-pol II promoters 
regardless of inducibility, the resulting shRNAs have to be transcribed as primary 
transcripts that are Drosha substrates which might lead to potential interference 
with the endogenous miRNA pathway. In addition, the final intracellular levels of 
the mature shRNA are lower than with RNA-pol III counterparts. On the one 
hand, this leads to lower gene silencing efficiencies but may on the other hand 
decrease undesired side effects (Boudreau et al., 2008; Li and Mahato, 2009 see 
also section 1.1.6.2).  
Mismatches in the shRNA stem can be beneficial as they may positively influence 
the strand selection process and therefore increase the specificity of a given 
shRNA (see section 1.1.8). However, it is important to mention that shRNAs with 
bulged stems have also been found to be less potent gene suppressors than their 
perfect stem counterparts (Mcintyre et al., 2006). Thus, given the number of 
different variables that have to be taken into account during shRNA design, it is 
still not clear which strategy is best suited for general use. Instead, the design 
has to be specifically adapted to the purpose of application. 
1.1.5 Strand terminologies 
The names used for the strands of different triggers of RNAi are sometimes ill-
defined which may lead to confusion among readers unfamiliar with the topic but 
also people working in the field. The terminology used in this study is therefore 
briefly defined. As aforementioned, the strand that is finally incorporated into 
active RISC is called “guide strand” whereas the discarded strand is termed 
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“passenger strand”. As this refers to single molecular events, in principle both 
physical strands of the small RNA duplex have the potential to become guide or 
passenger strand. However, in miRNA terminology the guide strand is classically 
the one that is mostly detected either by cloning or high-throughput analyses like 
miArray or deep sequencing with the other one being the star strand (e.g. miR-30 
and miR-30*) (Tomari and Zamore, 2005). Yet, by classical definition the star 
strand can also act as guide strand although usually with lower frequency than 
the designated guide strand. In fact, a number of studies have recently cast doubt 
on the original model that proposed only one mature strand per miRNA precursor 
(Ro et al., 2007; Kuchenbauer et al., 2011; Zhou et al., 2010; Yang et al., 2011). 
A more appropriate way is thus to term the strands according to their position 
within the miRNA precursor, i.e. at the 5’ or 3’ end as it is nowadays done in the 
miRNA database miRBase 18 (e.g. miR-124-5p and -3p as proposed by Ro et 
al., 2007). For miRNAs we will therefore stick to this strand definition.  
Artificial molecules like shRNAs and siRNAs are designed to specifically silence a 
gene with a perfectly complementary sequence stretch so that the target mRNA 
is defined as “sense” and the complement as “antisense” (Fire et al., 1998). The 
antisense strand of an si- or shRNA is thus the one that is supposed to be as 
active as possible whereas the sense strand that has exactly the same sequence 
as the mRNA target is supposed to be as inactive as possible. As in miRNAs, 
both strands have in principle equal opportunities to become either guide or 
passenger strand. A problem in terminology arises in the case of asymmetrical 
molecules like shRNAs where both sense and antisense strand can be located 
either at the 5’ or 3’ end of the molecule. The position of sense or antisense in the 
shRNAs used in this study will therefore be clearly indicated in each case. 
1.1.6 Side effects of exogenous triggers of RNAi 
1.1.6.1 Induction of the innate immune system 
The initial enthusiasm about the potency and specificity of targeted RNAi was 
dampened by a number of studies that reported potentially adverse side effects. 
For instance, the double-stranded exogenous RNA can be recognized by pattern 
recognition receptors which may lead to an interferon response (Bridge et al., 
2003). Regardless of the RNA sequence, this effect can depend on the presence 
of blunt ends or on the length of the double-stranded molecule in a cell type- 
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dependent manner (Reynolds et al., 2006; Marques et al., 2006). Moreover, 
interferon induction can also be sequence-specific, e.g. GU-rich dsRNAs were 
found to be more likely to trigger a response (Judge et al., 2005). Accordingly, the 
RNAi trigger should not exceed 29nt in length or contain blunt ends and certain 
immunostimulatory GU-rich sequences should be omitted when choosing the 
target site (Judge and Machlachlan, 2008). However, there may be more 
parameters that could influence stimulation of the innate immune system and that 
are currently unknown. In principle, the RNAi trigger of choice should therefore be 
carefully tested even when designed according to the abovementioned rules. 
1.1.6.2 Interference with the endogenous miRNA pathway 
In 2006, fatality in mice could be linked to high intracellular shRNA abundance 
after potent shRNA expression in mouse livers (Grimm et al., 2006a). This 
dramatic phenotype was independent of the shRNA sequence and unrelated to 
any activation of the innate immune system. Instead, it could be linked to the 
degree of shRNA expression and a concomitant competition for miRNA pathway 
components resulting in perturbation of miRNA functionality. This could be 
deduced from the finding that the toxicity could be partially relieved by 
overexpression of Exportin-5. Later on, overexpression of Ago2 also proved to 
alleviate shRNA-mediated toxicity to a certain extent (Grimm et al., 2010). 
Cytotoxicity from shRNA expression was also linked to tumor formation in mice 
(Beer et al., 2010). The initial findings were confirmed in other tissues like brain 
and heart muscle meaning that the deleterious effects of shRNA expression in 
vivo are not restricted to the liver but may affect organs throughout the whole 
body (McBride et al., 2008; Bish et al., 2011). In addition, expression of 
exogenous triggers of RNAi can result in decreased miRNA functionality in tissue 
culture, too (Khan et al., 2009). This may even lead to experimental failure and 
cytotoxicity in primary cells (Pan et al., 2011; An et al., 2006). As a result, the use 
of extremely strong promoters for shRNA expression -like the RNA-pol III U6 
promoter- is not recommended. Instead, either weaker RNA-pol III promoters like 
H1 or 7SK or RNA-pol II promoters can be used for shRNA expression 
(Castanotto et al., 2007; Giering et al., 2008; Grimm et al., 2010). 
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1.1.6.3 Off-targeting 
Aside from their designated target with perfect complementarity to the antisense 
strand, exogenous RNAi triggers also sequence-specifically bind untargeted 
cellular transcripts -so-called off-targets- and lead to their silencing (Fig. 2; 
Doench et al., 2003; Jackson et al., 2003). This can be explained by the fact that 
shRNA or siRNA are functionally similar to miRNAs which may have hundreds of 
different cellular targets due to the relatively low stringency of their target 
selection mechanism. It therefore seems logical that the antisense strand of 
exogenous RNAi triggers could also silence targets with partial complementarity 
in a miRNA-like fashion (Zeng and Cullen, 2003a). Likewise, the sense strand is 
also able to exert silencing on both perfect and imperfect targets. This off-
targeting was first experimentally addressed after transfection of siRNAs into 
mammalian cells (Jackson et al., 2003). In a follow-up study Jackson and 
colleagues reported that the same effect was observed with shRNAs, too, which 
could be confirmed by independent studies (Jackson et al., 2006a; Klinghoffer et 
al., 2010). Subsequently, they and other groups also showed that off-target 
effects are linked to seed matching between si/shRNA and 3’ UTR sequences of 
off-target genes proving that the underlying mechanism is indeed miRNA-like 
silencing (Birmingham et al., 2006). This was further confirmed by a study 
showing that hAgo2 slicing activity is not required for siRNA-mediated off-target 
effects (Vickers et al., 2009). Although the degree of silencing of untargeted 
genes is usually modest, off-targeting can still have deleterious side effects like 
experimental failure and toxic phenotypes (Fedorov et al., 2006; Schultz et al., 
2011; Grimm, 2011) 
1.1.7 Strategies to reduce off-targeting 
Naturally, tremendous efforts have been put into making exogenous RNAi 
triggers more specific. However, one major obstacle lies within the low fidelity of 
off-target prediction methods due to the same problems that hamper miRNA 
target prediction. It is therefore not possible to rationally design the sequences of 
si- or shRNAs to guarantee prevention of off-target silencing of specific genes 
(such as proto-oncogenes). It was furthermore shown that the profile of off-target 
effects is species-specific, thus adding another layer of complexity to the issue 
(Burchard et al., 2009). This means that potential therapeutic RNAi triggers 
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cannot be comprehensively tested in animal models to address possible off-
targeting-related side effects before going into patients. 
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Fig. 2: shRNA on- and off-target activi ties. In principle, both strands of an shRNA can be
active as RNAi trigger. The antisense strand mediates intended silencing of the designated
cellular target RNA which is def ined as „on-targeting“. However, both the antisense and the
sense strand can produce silencing of untargeted transcripts by either imperfect (i.e. miRNA-
like) or perfect binding sites. Ideally, an shRNA should produce maximal levels of intended
target silencing and minimal levels of of f-targeting. RISC = RNA-induced silencing complex.
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1.1.7.1 Chemical modifications and rational choice of sequence 
Certain chemical modifications at particular positions of siRNAs duplexes can 
beneficially influence target selectivity (Jackson et al., 2006b). These 
modifications allow selective inactivation of the siRNA sense strand and exclusive 
silencing of perfect targets by the antisense strand (Jackson et al., 2010). In 
addition, a plethora of different siRNA configurations and compositions has been 
proposed that all reduce off-target effects, for instance the incorporation of DNA 
or LNA nucleotides (Ui-Tei et al., 2008; Elmen et al., 2005). Yet, an ingenious 
study in 2008 also demonstrated the possibility to improve siRNA specificity by 
rational choice of the seed sequence (Anderson et al., 2008). Upon analysis of 
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the frequencies of all 4096 possible hexamers in human 3’ UTRs the authors 
found that some hexamers are present at much lower frequencies than others. 
By using such low frequency hexamers in siRNA seed regions they could 
considerably reduce the overall perturbation of gene expression produced by the 
siRNA. This design does not compromise activity of the respective strand per se 
but it reduces off-targeting simply by limiting the number of potential off-targets. 
In addition, using siRNA duplexes with high thermodynamic stability was reported 
to decrease off-target and increase on-target effects (Petri et al., 2011). Taken 
together, it is evident that a lot of different methods exist to guarantee a high 
degree of target specificity with synthetic siRNAs. 
However, most of these methods -i.e. any chemical modifications- are not 
applicable for shRNAs. A recent report therefore adopted the “safe seed” concept 
previously shown with siRNAs and proposed to design shRNAs in a way to 
contain seed regions with minimal frequencies of complementary sequences in 3’ 
UTRs of cellular genes (Boudreau et al., 2011). In addition, using seed regions 
with low melting temperatures in the seed-target duplex also reduce seed-
mediated off-target effects of shRNAs (Naito et al., 2009). While it is definitely 
advisable to take these strategies into account when designing new shRNAs, 
they are not always readily applicable. In the case of viral targets, for instance, 
the choice of the shRNA target site is often rather limited. This is due to the fact 
that many viruses present a high mutation rate during their replication cycle so 
that only those sequences that are highly conserved are suitable RNAi targets 
(Von Eije et al., 2008).  
1.1.7.2 Strand biasing mechanisms 
While there are no other means of making shRNA antisense strands more 
specific apart from using “safe” and low melting temperature seed regions, 
additional strategies have been devised to reduce sense strand-derived off-
targeting. These methods benefit from the fact that sense strand activity is not 
required for the desired silencing of the designated antisense target so that it can 
in principle be reduced to minimal levels without compromising shRNA potency.  
A certain reduction of sense strand activity can be achieved by using naturally 
occurring strand biasing mechanisms (Boudreau et al., 2008; Ding et al., 2008; 
Boudreau et al., 2011). The basis for this came from the notion that in most RNAi 
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triggers the two strands are not incorporated into RISC at equal frequencies. 
Mechanistic insights came from studies on siRNAs and miRNAs showing that the 
rate of incorporation of a given strand depends on the relative thermodynamic 
RNA duplex stability at its 5’ end (Schwarz et al., 2003; Khvorova et al., 2003). 
This means that the strand with the lower thermodynamic stability at its 5’ end 
has a higher likelihood of being used as guide strand. This may depend both on 
GC-content and existence of mismatches at either end of the duplex which is 
usually the case for miRNAs that rarely have perfectly matched stems. However, 
strand selection in miRNAs cannot be merely reduced to thermodynamic 
asymmetry of the duplex. Instead, the same pre-miRNA precursor can have a 
strong bias towards one strand in one tissue type but not in another indicating the 
involvement of additional, cell type-dependent factors (Ro et al., 2007). In 
addition, in miRNAs with strong strand biasing a 5’ cytosine was linked to the 
lower expressed strand while high purine content and a 5’ uracil were shown to 
be characteristics of the higher expressed strand (Hu, 2009). The structural basis 
for the latter seems to lie in specific interactions between 5’ uracil and a 
conserved loop within the hAgo2 Mid domain (Frank et al., 2010). Implementation 
of these findings for optimal shRNA design is challenging as it is not always 
possible to find a suitable target site that is compatible with the abovementioned 
rules. 
Besides via thermodynamic stability a certain strand bias may also be introduced 
by Dicer processing. The use of perfect RNA duplex molecules with DNA 
nucleotides at one end that only allowed Dicer processing from one side revealed 
a functional polarity towards the strand that carries a 2nt 3’ overhang and that is 
thus bound by Dicer (Rose et al., 2005). In shRNAs with perfect stems it is only 
the 3’ strand that possesses a 3’ overhang and, indeed, a general functional bias 
towards this strand has been shown (Boudreau et al., 2008). However, a recent 
study reported that small RNA duplexes are first released from Dicer after 
cleavage and then rebound and repositioned according to their thermodynamic 
asymmetry (Noland et al., 2011). This model suggests that there is no general 
mechanism that favors incorporation of the strand that is initially bound by Dicer 
but, instead, completely refers to thermodynamic asymmetry. Yet another study 
claims that Dicer does not contribute to asymmetric RISC loading at all (Betancur 
and Tomari, 2012). The mechanistic basis for the functional strand bias observed 
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by Rose and colleagues is thus not clear. Nevertheless, the standard design of 
RNA-pol III shRNA places the antisense strand at the 3’ end of the hairpin 
molecule (Mcintyre et al., 2011). To further increase the strand bias, strategies 
have been designed that introduce mismatches at the 5’ end of the antisense 
strand, thus employing the thermodynamic stability rule (Ding et al., 2008; 
Boudreau et al., 2011). However, none of the studies convincingly showed 
reduction of shRNA sense strand activity to levels that do not contribute to off-
targeting anymore under therapeutically relevant conditions, particularly upon 
expression from viral vectors. 
 
1.2 Hepatitis C virus 
Hepatitis C virus (HCV) is an enveloped, positive-sense single-stranded RNA 
virus of the family Flaviviridae and the causative agent of hepatitis C in humans. 
The viral core consists of the RNA genome surrounded by an icosahedral shell of 
core proteins (Bartenschlager et al., 2011). The core is enclosed by a lipid 
envelope. A transmembrane domain of the core proteins links the core to two 
viral glycoproteins E1 and E2 that are embedded in the envelope. Core and 
envelope form particles of around 60nm in size. 
The HCV genome harbors a single open reading frame (ORF) of 9600 
nucleotides (Bartenschlager and Lohmann, 2000).  Translation of the ORF starts 
via an internal ribosomal entry site (IRES) producing a single protein product that 
is then proteolytically cleaved to yield smaller active proteins. The 5' and 3' ends 
of the RNA consist of non-translated regions (NTRs) that are important for 
translation and replication of the viral RNA (Friebe and Bartenschlager, 2009). 
Due to the high mutation rate during HCV replication a wide variety of different 
HCV genotypes exist (Kuiken and Simmons, 2009). The different genotypes 
result in different disease progressions and have different susceptibilities to 
antiviral treatments (see below). 
1.2.1 HCV replication 
HCV replicates mainly in hepatocytes but may also reside in peripheral blood 
mononuclear cells (Zignego et al., 1992). After viral entry and release of the RNA 
genome into the cytoplasm a first round of translation occurs that yields a 
polyprotein that is proteolytically cleaved into smaller active proteins 
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(Bartenschlager and Lohmann, 2000). One of the proteins is the viral RNA-
dependent RNA polymerase NS5B that subsequently produces a negative strand 
template for further production of positive sense genomes. NS5B activity is highly 
error-prone leading to high mutation rates during HCV replication (Contreras et 
al., 2002). Replication of the viral genome occurs in a membranous web that is 
induced by another virally encoded protein, NS4B, and that is derived from the 
endoplasmic reticulum (ER) membrane (Alvisi et al., 2011). Genomes are then 
translated, further replicated or packaged into new virus particles that bud from 
the cells and spread the infection.  
The human liver-specific miRNA miR-122-5p binds to a specific target sequence 
at the 5’ end of the HCV genome (Jopling et al., 2005). However, miR-122-5p 
does not inhibit HCV as could be expected from the natural mode of action of 
miRNAs. Instead, miR-122-5p binding protects the HCV 5’ end and leads to 
markedly increased viral replication and thus seems to act as an important co-
factor for replication (Jopling et al., 2005; Shimakami et al., 2011). This is the only 
example of a miRNA positively influencing the translation and stability of a target 
RNA.  
1.2.2 HCV therapies 
There are an estimated 170 Mio HCV-infected individuals worldwide. Around 
80% of infections lead to a chronic progression which is the primary cause of liver 
cirrhosis and hepatocellular carcinoma with 10-30% of infected subjects 
developing cirrhosis over 30 years (Rosen, 2011). The standard treatment for 
HCV genotypes 2 and 3 consists of pegylated interferon alpha (PEG-IFNa) and 
the antiviral drug ribavirin leading to viral eradication in around 85% of patients 
(Bühler and Bartenschlager, 2012). For HCV genotype 1 which is the most 
prevalent world-wide the probability of therapeutic success is lower with this 
therapy. A novel treatment has therefore recently been admitted for genotype 1 in 
the US that combines the standard treatment with the protease inhibitors 
boceprevir and telaprevir which improves the outcome of therapy (Bühler and 
Bartenschlager, 2012).  
Current treatments have vastly icreased the survival rates of infected individuals 
but therapy is not always successful. Moreover, treatment of chronic infection 
with PEG-IFNa and ribavirin is expensive and can produce severe side effects. 
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Thus, alternative strategies are developed to effectively counteract or even cure 
chronic infection without the need of PEG-IFNa. In a recent clinical trial, a 
combination of a protease inhibitor, a NS5B polymerase inhibitor and ribavirin 
was shown to efficiently clear HCV after only 30 days of treatment without strong 
side effects (Zeuzem et al., 2011). In another clinical trial, HCV could be 
counteracted by miR-122 inhibition via locked nucleic acid (LNA) probes with a 
phosphothioesterate backbone (source: www.santaris.com). These approaches 
offer promising new treatment strategies but long-term patient progression has 
yet to be determined. Another approach that is not at the stage of clinical trials 
yet, but that also holds promise for the treatment of HCV infection is RNAi-based 
gene therapy (Grimm and Kay, 2006). In this strategy, a single gene therapeutic 
treatment could ideally lead to life-long resistance to the virus. A number of 
studies have shown the effectiveness of vector-encoded shRNAs against HCV 
(Kapadia et al., 2003; Wilson et al., 2003; Randall et al., 2003). To avoid viral 
escape from RNAi treatment due to mutations the shRNAs are commonly 
directed against conserved sequences within the HCV genome (Wilson and 
Richardson, 2005; Yang et al., 2010b). The suitability of conserved target sites 
within the HCV 5’NTR as RNAi targets was comprehensively shown by Krönke 
and colleagues in 2004 (Krönke et al., 2004). In addition, combinatorial RNAi 
strategies have been tested that express several shRNAs at the same time 
making viral escape less likely (Yang et al., 2010b).  
 
1.3 Adeno-associated virus 
1.3.1 Wildtype AAV 
Adeno-associated virus (AAV) is a non-enveloped, helper-dependent virus that 
belongs to the family of Parvoviridae (Berns and Giraud, 1995). With a diameter 
of around 20nm it is among the smallest known viruses. The single-stranded 
DNA (ssDNA) genome of wildtype AAV (wtAAV) only encodes two genes that 
give rise to a total of 8 proteins (Sonntag et al., 2010). Two promoters p5 and p19 
drive expression of two overlapping mRNAs that are both alternatively spliced 
resulting in 4 different gene products. As these products are implicated in AAV 
replication, the corresponding genes are called rep genes and the encoded 
proteins Rep78, Rep68, Rep52 and Rep40, according to their molecular weight. 
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Another promoter -p40- drives expression of the assembly factor AAP and the 
three structural AAV proteins VP1-3 that are produced in a ratio of 1:1:10 and 
together form the viral capsid (Sonntag et al., 2010; Rose et al., 1971). The 
corresponding gene was therefore termed cap gene.  
 
Fig. 3: Wildtype AAV and recombinant AAV technology. A: Wildtype AAV (wtAAV) carries
two genes involved in replication (rep) or packaging (cap). The only sequence elements
required for packaging in cis are the inverted terminal repeats (ITRs). Recombinant AAVs
(rAAVs) can therefore be generated by packaging transgenes f lanked by ITRs into AAV
capsids. Single-stranded rAAVs replicate like wtAAV and carry a single stranded DNA copy of
the transgene. Self -complementary vectors have one mutated ITR. This leads to the
generation of inverted repeats during vector replication that can fold back and permit faster and
enhanced transgene expression upon transduction. Adapted from Mockenhaupt and Grimm,
2011. B: Transgenes f lanked by AAV ITRs can be pseudotyped with naturally occuring capsids
from other WT serotypes or with synthetic capsids that carry peptide insertions or that are
shuff led from different serotypes. This allows generation of particles with characteristics -
especially tropisms- tailored to the application.
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The rep and cap genes are flanked by inverted terminal repeats (ITRs) on either 
side. The ITRs have essential functions for AAV genome replication as their 
structure allows self-priming which subsequently permits the cellular replication 
machinery to initiate the replication reaction without the need for a primase (Xiao 
et al., 1997). In addition, they also harbor the so-called terminal resolution site 
(trs). The trs is a particular DNA sequence targeted by the AAV replication protein 
Rep78 that generates a DNA single-strand break which then allows the double-
stranded replication intermediate to be dissociated into two mature ssDNA AAV 
genomes that are ready for packaging (Snyder et al., 1993). Unlike other 
parvoviruses, AAV packages both single-stranded versions of its genome so that 
particles with both genome polarities coexist (Berns and Adler, 1972). WtAAV 
site-specifically integrates with high frequency at a certain locus on human 
chromosome 19 which was termed AAVS1 (Kotin et al., 1990). Integration into 
AAVS1 depends on Rep68 and 78 (Surosky et al., 1997). Furthermore, AAV is 
able to infect both dividing and non-dividing cells (Flotte et al., 1994; Podsakoff et 
al., 1994). It produces only a mild innate immune response but robust humoral 
immunity (Zaiss et al., 2002). The latter may pose potential problems for 
employing AAV as gene therapy vector. However, these issues can be largely 
circumvented by the use of engineered AAV serotypes (see below). 
1.3.2 Recombinant AAV technology 
The only wtAAV features required in cis for packaging into particles are the two 
ITRs (Xiao et al., 1997). The rep and cap genes can be readily delivered in trans 
which makes it easy to package a totally unrelated sequence into AAV capsids 
(Fig. 3A). Such a particle that carries genetic material other than the WT genome 
is called recombinant AAV (rAAV).  
1.3.2.1 Characteristics of rAAV 
To date, there are at least 12 different wtAAV serotypes plus hundreds of isolates 
available whose most important difference lies within their cap sequences 
(Grimm and Kay, 2003). The resulting AAV particles vary considerably in their 
tropisms. For example, AAV8 has a strong but not exclusive liver tropism in mice 
whereas AAV1 is more efficient at infecting heart muscle cells (Gao et al., 2002; 
Inagaki et al., 2006). Besides the naturally occurring serotypes, an ever-
expanding plethora of synthetic capsids further broadens the spectrum of cell 
29 
 
INTRODUCTION 
______________________________________________________________________________ 
types that are susceptible to AAV infection. DNA family shuffling methods or 
peptide insertions into specific position within the capsid proteins followed by 
AAV library-based selections hold promise to target virtually any cell type of 
choice (Grimm et al., 2008). Importantly, most ITRs are compatible with 
packaging into capsids from another serotype so that transgenes flanked by ITRs 
from the commonly used AAV2 serotype can be readily pseudotyped with 
different capsids (Fig. 3B; Rabinowitz et al., 2002; Grimm et al., 2006b). This 
allows easy production of particles with tropisms matched to the experimental or 
therapeutic setup which greatly facilitates the use of rAAV as gene therapy vector 
and as an in vitro or in vivo transduction reagent.  
Like wtAAV, rAAV can infect both dividing and non-dividing cells which is 
essential for using it as gene transfer vehicle in vivo as most cells in the body of 
mammals are quiescent in their normal state (Flotte et al., 1994; Podsakoff et al., 
1994). However, there is no site-specific integration into AAVS1 as the vectors do 
not express the required Rep proteins. Instead, they circularize in vivo via their 
ITRs and can persist indefinitely as episomes thus allowing long-term transgene 
expression without vector integration (Yan et al., 2005; Kaplitt et al., 1994; 
Podsakoff et al., 1994). One potential drawback of rAAVs is the low packaging 
capacity of up to 5.2kb (Dong et al., 1996). While this does not allow delivery of 
large transgenes it is irrelevant for the transfer of short sequences such as 
shRNA expression cassettes that were used in this study. 
1.3.2.2 Self-complementary AAV 
Upon AAV infection, the particle trafficks to and into the nucleus where it is 
uncoated to release the ssDNA genome. For conventional rAAV vectors with 
ssDNA genomes (ssAAVs) the second DNA strand then has to be synthesized or 
complemented by a ssDNA genome of opposite polarity before any gene 
expression can occur; a step that rate-limits AAV-mediated transduction (Ferrari 
et al., 1996; Fisher et al., 1996; Nakai et al., 2000). To overcome this issue, so-
called self-complementary rAAV (scAAV) vectors were designed (McCarty et al., 
2003). For their generation, the trs of one of the two ITRs is mutated so that it 
cannot be nicked by Rep78 anymore. During replication of such structures the 
ensuing intermediates cannot be separated leading to a double-sized genome 
that forms a large inverted repeat. This inverted repeat genome is then packaged 
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as ssDNA into rAAVs. Upon infection, the genome rapidly folds into a dsDNA 
form and thus permits faster and enhanced gene expression both in tissue 
culture and in vivo as compared to ssAAVs. A drawback of scAAV vectors is the 
even smaller packaging capacity which is reduced to 2.2kb although this is no 
obstacle for shRNA delivery as mentioned before. All rAAVs used in this study 
were of the self-complementary type. 
1.3.2.3 rAAV as gene therapy vectors 
Until January 2012, rAAV vectors had been tested in 86 clinical trials with 12 of 
them being in phase II and 8 in phase III (source: The Journal of Gene Medicine, 
see section 6.2. for weblink). The range of diseases that are to be treated is 
extremely diverse and administration can be both local and systemic. Importantly, 
these trials show that rAAVs are versatile, potent and safe vectors for gene 
therapeutic applications. 
 
1.4 shRNAs and rAAV vectors 
1.4.1 Application in gene therapy 
siRNAs are commonly used in tissue culture experiments. However, not all cell 
types are easy to transfect and, likewise, the main obstacle of using synthetic 
siRNAs in vivo is the difficulty of efficient systemic delivery rendering certain 
therapeutic applications impossible at this point. In addition, the effect of siRNAs 
is only transient which is not desirable in every application. Starting in the early 
2000s, expressed shRNAs were tested as gene therapeutic silencing tool and 
combined with viral vectors -including rAAV- in the hope of finding ways of 
treating a wide range of different diseases that could not be treated otherwise. 
Highly promising results were obtained in proof-of-principle tissue culture studies 
for the treatment of diseases ranging from CNS disorders over viral infections to 
cancer (Grimm and Kay, 2007a). However, in pre-clinical in vivo studies 
expression of RNAi triggers was linked to cytotoxicity and fatality in mice (see 
section 1.1.6.2) which temporarily dampened the belief in the therapeutic 
potential of the technology. Fortunately, the use of weaker promoters and 
inducible expression strategies is starting to overcome this issue so that in the 
long run a therapeutic implementation seems possible. Given the flexibility in 
tropism and their high in vivo transduction efficiencies, rAAV vectors are 
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particularly interesting for the delivery of shRNA-based therapeutics to a variety 
of different tissues, especially liver, heart and brain (Danos, 2008). 
1.4.2 Application in functional genomics 
A second important application of RNAi triggers lies in functional genomics. 
Again, shRNAs expressed from viral vectors are able to overcome the 
abovementioned restrictions with siRNAs. On the one hand, this may facilitate 
studies that examine the function of particular genes. rAAV is an ideal candidate 
for such studies, especially if gene functions should be unraveled in vivo. On the 
other hand, virally-encoded shRNAs can increase the power of RNAi screens 
(Blakely et al., 2011). This requires the generation of viral vector-based shRNA 
libraries which is much more challenging than producing siRNA libraries. 
However, once established these shRNA libraries offer a considerably higher 
versatility and thus applicability than siRNAs. While the most commonly used 
shRNA libraries are based on lentiviral vectors, rAAV could be an attractive 
alternative under certain experimental conditions (Danos, 2008). 
 
1.5 Research questions and objectives 
In this study, we aimed at improving current strategies for therapeutic shRNA 
expression. Specifically, we wanted to reduce off-target effects derived from 
shRNA sense strands to increase specificity and hence reliability of RNAi triggers 
for potential use in antiviral therapy. Our therapeutic target model system was 
hepatitis C virus. 
We first focused on functionally characterizing previously published shRNAs with 
particular interest in the relative activities of sense and antisense strands. As we 
were aiming at maximal antisense strand potency we focused our work on RNA-
pol III-transcribed “classical” shRNAs with perfectly matched stems that are more 
efficient in silencing their designated targets than other types of hairpins (see 
section 1.1.4). Our functional shRNA analysis allowed us to formulate some 
design rules that were next applied to generate an shRNA targeting a conserved 
sequence in the HCV 5’NTR. We subsequently further improved the anti-HCV 
shRNA expression vector by applying a novel strategy to reduce sense strand 
activity without altering antisense strand activity. Our method allowed us to 
decrease off-target effects without compromising HCV inhibition. The improved 
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system was tested in combination with rAAV-mediated gene delivery which 
represents a promising and powerful tool for in vivo application of RNAi 
therapeutics. Last but not least, we also examined the applicability of our strategy 
for reduction of sense strand activity with other shRNAs and tested the use of our 
expression vector design for purposes other than sense strand inhibition. 
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2 MATERIALS AND METHODS 
2.1 Plasmid construction 
For the construction of pBS-U6-CMV-empty, the CMV promoter was amplified 
from pDB2-EGFP-attB (Keravala et al., 2006) by CMV F/CMV R, digested with 
XhoI/BamHI and inserted into SalI/BamHI-digested pBS-U6-GFP (Grimm et al., 
2006a). Then, RSV-EGFP was amplified from pBS-U6-GFP with RSV F/EGFP R 
and BamHI/SpeI digested so that the EGFP cDNA could be inserted into the 
BamHI/NheI sites of the cloning intermediate. EGFP R introduces an AvrII/SalI 
cloning site in the EGFP 3’ UTR for insertion of shRNA binding sites. pBS-H1-
CMV-empty was generated by transferring the H1-empty cassette from pBS-H1-
GFP (Grimm et al., 2006a) into the same sites of pBS-U6-CMV-empty. 
shHCV318 annealed oligos were directly cloned into BbsI-digested pBS-H1-
CMV-empty to yield pBS-H1-shHCV318-CMV-empty. This plasmid was further 
modified by insertion of a HCV318 target site into AvrII/SalI via annealed oligos 
HCV318-sponge F/R. pBS-U6-hAAT19-CMV-empty was generated by transfer of 
the AscI/NotI digested U6-hAAT19 cassette from pBS-U6-hAAT19-GFP (Grimm 
et al., 2006a) into the same sites of pBS-U6-CMV-empty. For hAAT sponge 
construction, we concatemerized four hAAT binding sites by sequential cloning of 
hAAT sponge F/R first into AvrII/SalI and then into NheI/SalI. 
To construct pBS-H1-TuD-empty-GFP and pBS-U6-TuD-empty-GFP, the 
annealed oligos TuD empty F/R were inserted into BbsI-digested pBS-H1-GFP or 
pBS-U6-GFP, respectively (Grimm et al. 2006a). Next, the entire H1-TuD-empty 
cassette was amplified with primers H1 F/TuD R and nt27-676 of the EGFP 
cDNA were amplified from pBS-H1-GFP with the primers EGFP stuffer F/R. The 
latter was supposed to function as stuffer and spacer sequence between the 
shRNA and the TuD cassette. Both fragments were joined by overlap extension 
PCR, digested with XbaI/SalI and inserted into NheI/SalI of pBS-H1-GFP to yield 
pBS-H1-H1-TuD-empty. Using the same strategy, we generated pBS-H1-U6-
TuD-empty using primer U6 F and pBS-U6-TuD-GFP as template. As a results of 
this vector design the shRNA cassette remains excisable by unique AscI/NotI 
sites and the TuD cassette can be cut out via unique NheI/SalI sites. TuD target 
sites were inserted into the TuD-empty scaffold either by cloning of annealed 
oligos or PCR-amplified annealed oligos into BsmBI-digested pBS-H1-H1-TuD-
34 
 
                                                                                    MATERIALS AND METHODS 
______________________________________________________________________________  
 
empty or pBS-H1-U6-TuD-empty. ShRNAs were generated either by insertion of 
annealed oligos into BbsI-digested pBS-H1-H1-TuD-empty or by cloning of an 
already existing shRNA cassette that was excised from either pBS-H1-GFP or 
pBS-U6-GFP by AscI/NotI and inserted into the same sites of pBS-H1-H1-TuD-
empty. The entire sequence was flanked by two AAV ITRs which allows 
packaging of both shRNA and TuD into rAAVs. For a schematic representation of 
the shRNA-TuD vectors used in this study, please refer to Fig. 11A. The miR-
122-5p TuD vector was cloned by insertion of annealed TuD-M122 F/R oligos 
into BsmBI-digested pBS-H1-TuD-empty-GFP. 
Anti-hAAT, anti-sAg and anti-P53 shRNAs were available in the lab from previous 
studies (Grimm et al., 2006a; Beer et al., 2010). 
Luciferase reporter constructs carrying single target sites were generated by 
insertion of annealed oligos carrying the respective binding site into XhoI/NotI in 
psiCheck-2 (Promega).  
hAAT random target reporters were generated by annealing of 1µl each of hAAT 
randtarg F and hAAT randtarg R and subsequent elongation by Sequenase (usb) 
according to the manufacturers guidelines. The elongated dsDNA was digested 
with XhoI/NotI and inserted into the same sites of psiCheck-2 (Promega).  
3’ UTR reporters for shHCV318 off-target measurement were generated by PCR 
amplification of the respective 3’ UTR or parts thereof using the primers indicated 
below, SalI/NotI digestion and insertion into XhoI/NotI of psiCheck-2 (Promega). 
For generation of pSSV9-DualFluor-empty the bidirectional CMV promoter plus 
d2EGFP cDNA were amplified from pSMB-miMeasure (Heidelberg iGEM team 
2010) with biCMV F and d2EGFP R. A minimal poly(A) was amplified from 
psiCheck-2 (Promega) with minimal p(A) F and R. biCMV-d2EGFP was digested 
with BglII/XhoI and the minimal poly(A) with SpeI/XhoI and both fragments were 
inserted into BglII/SpeI digested pSSV9-AAV2-SpeI in a single ligation reaction. 
The resulting pSSV9-biCMV-EGFP was digested with HindIII/BamHI and 
mCherry-SV40-poly(A) digested with the same enzymes from psiFluor-2* was 
inserted. 
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2.2 Oligonucleotides 
2.2.1 General cloning 
Primer name Sequence 5’ ? 3’ (restriction sites in bold) 
CMV F TGTAC CTCGAG GTTACATAACTTACGGTAAATGGCC 
CMV R TTAG GGATCC GGATCTGACGGTTCACTAAACCAG 
RSV F CAATTCTCATGTTTGACAGC 
EGFP R GT ACTAGTCGAC TATTG CCTAGG CTTTACTTGTACAGCTCGTCCATG 
TuD empty F CACC GACGGCGCTAGGATCATCCCA GAGACG AC CGTCTC 
ACCGATGATCCTAGCGCCGTC 
TuD empty R AAAA GACGGCGCTAGGATCATCGGT GAGACG GT CGTCTC 
TGGGATGATCCTAGCGCCGTC 
H1 F GGTCCTGCTGGAGTTCGTGA GCTAGC CATATTTGCATGTCGCTATGTGTTC 
U6 F GGTCCTGCTGGAGTTCGTGA GCTAGC CGAGTCCAACACCCGTGGGAATC 
TuD R TTAG GTCGAC CGGCCGCAAAAAAGACGGCGCTAG 
EGFP stuffer F TTAGT ACTAGT CACCGGGGTGGTGCCCATCCTG 
EGFP stuffer R TCACGAACTCCAGCAGGACCATG 
GFP R GT ACTAGTCGAC TATTG CCTAGG CTTTACTTGTACAGCTCGTCCATG 
biCMV F TCGA AGATCT GGATCC TAAGA AAGCTT GCGATCTGACGGTTCACTAAACG 
d2EGFP R TCGA ACTAGT TAGTC CTCGAG CGATCGCCTAGAA 
CTACACATTGATCCTAGCAGAAGC 
minimal poly(A) F GATCGCTCGAGCCCGGGAATTCG 
minimal poly(A) R TCGA ACTAGT CACACAAAAAACCAACACACAGATG 
2.2.2 shRNA oligonucleotides 
Oligo name Sequence 5’ ? 3’ (antisense sequence underlined, overhangs in lower case) 
hAAT19 F cacc GAAGCGTTTAGGCATGTTT TCAAGAG AAACATGCCTAAACGCTTC 
hAAT19 R aaaa GAAGCGTTTAGGCATGTTT CTCTTGA AAACATGCCTAAACGCTTC 
hAAT25 F cacc GAAGCGTTTAGGCATGTTTAACATC TCAAGAG 
GATGTTAAACATGCCTAAACGCTTC 
hAAT25 R aaaa GAAGCGTTTAGGCATGTTTAACATC CTCTTGA 
GATGTTAAACATGCCTAAACGCTTC 
sAg21SA F cacc GTTTACTAGTGCCATTTGTTC CTAAGAG GAACAAATGGCACTAGTAAAC 
sAg21SA R aaaa GTTTACTAGTGCCATTTGTTC CTCTTAG GAACAAATGGCACTAGTAAAC 
shHCV318 F cacc GGGAGGTCTCGTAGACCGTGCA CTAAGAG 
TGCACGGTCTACGAGACCTCCC 
shHCV318 R aaaa GGGAGGTCTCGTAGACCGTGCA CTCTTAG 
TGCACGGTCTACGAGACCTCCC 
shHBVS1 F cacc GGTATGTTGCCCGTTTGTCT TCAAGAG AGACAAACGGGCAACATACC 
shHBVS1 R aaaa GGTATGTTGCCCGTTTGTCT CTCTTGA AGACAAACGGGCAACATACC  
shHBVS1-22nt 
F 
cacc GGTATGTTGCCCGTTTGTCTTC TCAAGAG 
GAAGACAAACGGGCAACATACC 
shHBVS1-22nt 
R 
aaaa GGTATGTTGCCCGTTTGTCTTC TCAAGAG 
GAAGACAAACGGGCAACATACC 
2.2.3 3’ UTR targets 
Oligo name Sequence (5’ ? 3’, overhangs in lower case)
sAg-S F tcga CTCAGTTTACTAGTGCCATTTGTTC 
sAg-S R ggcc GAACAAATGGCACTAGTAAACTGAG 
sAg-AS F tcga GAACAAATGGCACTAGTAAACTGAG 
sAg-AS R ggcc CTCAGTTTACTAGTGCCATTTGTTC 
hAAT-S F tcga GAAGCGTTTAGGCATGTTTAACATC 
hAAT-S R ggcc GATGTTAAACATGCCTAAACGCTTC 
hAAT-AS F tcga GATGTTAAACATGCCTAAACGCTTC 
hAAT-AS R ggcc GAAGCGTTTAGGCATGTTTAACATC 
hAAT-AS-b11CT F tcga GATGTTAAACATGCTTAAACGCTTC 
hAAT-AS-b11CT R ggcc GAAGCGTTTAAGCATGTTTAACATC 
HCV318-S F tcga GGGAGGTCTCGTAGACCGTGCA 
HCV318-S R ggcc TGCACGGTCTACGAGACCTCCC 
HCV318-AS F tcga TGCACGGTCTACGAGACCTCCC 
HCV318-AS R ggcc GGGAGGTCTCGTAGACCGTGCA 
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HCV318-AS b11CT F tcga TGCACGGTCTATGAGACCTCCC 
HCV318-AS b11CT R ggcc GGGAGGTCTCATAGACCGTGCA 
HBVS1-S F tcga GGTATGTTGCCCGTTTGTCT 
HBVS1-S R ggcc AGACAAACGGGCAACATACC 
HBVS1-AS F tcga AGACAAACGGGCAACATACC 
HBVS1-AS R ggcc GGTATGTTGCCCGTTTGTCT 
HBVS1-AS-b11GC F tcga AGACAAACGCGCAACATACC 
HBVS1-AS-b11GC R ggcc GGTATGTTGCGCGTTTGTCT 
P53P7-S F tcga GGAGCTGAATGAGGCCTTAGA 
P53P7-S R ggcc TCTAAGGCCTCATTCAGCTCC 
P53P7-AS F tcga TCTAAGGCCTCATTCAGCTCC 
P53P7-AS R ggcc GGAGCTGAATGAGGCCTTAGA 
sh122-AS F tcga TGGAGTGTGACAATGGTGTTTGT 
sh122-AS R ggcc ACAAACACCATTGTCACACTCCA 
hAAT randtarg F TGAC CTCGAG GATGTTAAACATGNNNAAACGCTTC GCGGCCGC 
TGACTT 
hAAT randtarg R AAGTCA GCGGCCGCGAAG 
CLCN7 3'UTR F GATA GTCGAC GGCCCAGCCCTGCCCATAATGG 
CLCN7 3'UTR R GATTA GCGGCCGC GCCCTGTGAGGGCTAAGCAGGG 
BCL7B 3'UTR F GATA GTCGAC CACCATCCCGGCCCTCCGCC 
BCL7B 3'UTR R GATTA GCGGCCGC TATGTCTTCACTCACTGTTGCCC 
FRMD8 3'UTR F GATA GTCGAC GGACGCTGCACCCGGCAGGAG 
FRMD8 3'UTR F GATTA GCGGCCGC GCAAGACCGAGCAACTCCAGGAC 
CIRBP 3UTR F AATA GTCGAC AAACCCTTCCTGCTCAAGATCG 
CIRBP 3UTR R AATTA GCGGCCGC GTGCACGTCCACTGTCCCTGC 
2.2.4 Sponge target sites 
Oligo name Sequence 5’ ? 3’ (restriction sites in bold, overhangs in lower case) 
HCV318-sponge F ctagg TAGA TGCACGGTCTATGAGACCTCCC GCTAGCTACTG g 
HCV318-sponge R tcgac CAGTAGCTAGC GGGAGGTCTCATAGACCGTGCA TCTA c 
hAAT-sponge F ctagg TTAAACATGCaTAAACGCTTC TGA TTAAACATGCCGAAACGCTTC 
GCTAGCTAC g 
hAAT-sponge R tcgac GTAGCTAGC GAAGCGTTTCGGCATGTTTAA TCA 
GAAGCGTTTATGCATGTTTAA c 
2.2.5 TuD target sites 
Oligo name Sequence 5’ ? 3’ (restriction sites in bold, overhangs in lower case) 
For direct cloning  
TuD-hAAT F tcccaTTAAACATGCATAAACGCTTCCAAGTATTCTGGTCACAGAATACAAC 
TTAAACATGCCGAAACGCTTC a 
TuD-hAAT R tcggt GAAGCGTTTCGGCATGTTTAA 
GTTGTATTCTGTGACCAGAATACTTG GAAGCGTTTATGCATGTTTAA t 
TuD-HBVS1 F tccca AGACAAACGTGCAACATACC 
CAAGTATTCTGGTCACAGAATACAAC AGACAAACGAGCAACATACC a 
TuD-HBVS1 R tcggt GGTATGTTGCTCGTTTGTCT GTTGTATTCTGTGACCAGAATACTTG 
GGTATGTTGCACGTTTGTCT t 
TuD-M122 F tccca CAAACACCATGCCAACACTCCA 
CAAGTATTCTGGTCACAGAATACAAC CAAACACCATGCCAACACTCCA a 
TuD-M122 R tcggt TGGAGTGTTGGCATGGTGTTTG 
GTTGTATTCTGTGACCAGAATACTTG TGGAGTGTTGGCATGGTGTTTG t 
For overlap extension  
TuD-HCV318 F AATA GGTCTC G TCCCA AGCACGATAAATGAGACCTCCC 
CAAGTATTCTGGTCACAGAATA, 
TuD-hAATSp F AATA CGTCTC G TCCCA AGCGTTTAGGCATGTTTAACAT 
CAAGTATTCTGGTCACAGAATA 
TuD-hAATp F AATA CGTCTC G TCCCA TTAAACATGCCTAAACGCTTC 
CAAGTATTCTGGTCACAGAATA 
TuD- HCV318p R AATA CGTCTC G TCGGT GGGAGGTCTCGTAGACCGTGCA 
GTTGTATTCTGTGACCAGAATA 
TuD-HCV318 R AATA GGTCTC G TCGGT GGGAGGTCTCATAGACCGTGCA 
GTTGTATTCTGTGACCAGAATA  
TuD-hAATp R AATA CGTCTC G TCGGT GAAGCGTTTAGGCATGTTTAAC 
GTTGTATTCTGTGACCAGAATA 
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2.3 PCR 
In general, 50µl PCR reactions were set up as follows: 
Component Amount 
5x Phusion® HF Buffer 10µl 
FWD primer (100µM) 0.5µl (final conc.: 1µM) 
REV primer (100µM) 0.5µl (final conc.: 1µM) 
Plasmid template (1-10ng/µl)* 1µl 
Phusion® Hot Start II DNA 
Polymerase (2U/µl) 
0.5µl (final: 1U) 
dH2O Ad 50µl 
* for extension PCRs of two overlapping oligos, no template was added 
 
Cycling was conducted in a FlexCycler (AnalytikJena) with the following cycling 
conditions: 
30s, 98°C 
35 cycles of 
10s, 98°C 
15s, variable temp; adjusted as Tm-3 of the lower Tm primer 
30s/kb of amplicon length, 72°C 
1min, 72°C 
Forever, 4°C 
 
2.4 Molecular cloning 
2.4.1 Preparative restriction digestion 
For a standard cloning procedure, 2µg of both receiver and donor plasmid were 
digested for at least three hours with 0.5µl (2-10U, depending on the enzyme 
concentration) of each restriction enzyme in an appropriate restriction buffer 
(activities >75% according to manufacturer’s information) at the recommended 
incubation temperature. For cloning of PCR products, the whole PCR reaction 
(typical yields are 1-2µg) was gel purified through a 1% agarose gel in 1xTAE 
buffer (QIAquick Gel extraction kit, QIAGEN), eluted in 30µl dH2O and digested 
in the same way as explained above. A standard restriction reaction looked as 
follows: 
Component Amount (plasmid / PCR)
10x restriction buffer 2µl / 3.5µl 
Plasmid vector / PCR 2µg / 30µl 
Restriction enzyme (4-20U/µl) 0.5µl  
dH2O Ad 20µl / 35µl 
 
Restriction digests were gel purified and eluted in 30µl dH2O.  
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2.4.2 Ligation and transformation 
Ligation was conducted in 10µl reactions and incubated for 30-90min at room 
temperature: 
 
Component Amount 
10x T4 ligation buffer (NEB) 1µl 
Digested backbone 1.5µl 
Digested insert / annealed oligos 7µl / 1µl 
T4 DNA ligase (NEB) 0.5µl 
dH2O Ad 10µl 
 
After incubation, the ligation mix was incubated for 5min on ice. Per ligation 
reaction, 50µl of chemocompetent E.coli (DH5alpha) were thawed on ice in 
parallel. The bacteria were then mixed with the ligation mix and incubated on ice 
for 10-15min, followed by a heat shock at 42°C for 45-60s in a heating block (MB-
102, BIOER) and subsequent incubation on ice for 5min. After that, the 
transformation mix was plated as a whole on LB-agar plates containing 50µl/ml 
ampicillin and incubated overnight at 37°C. 
2.4.3 Identification of positive clones 
For screening of correct clones, typically 2-3 colonies were picked per construct 
and incubated for 8h or overnight in 3ml LB media containing 50µg/ml ampicillin. 
2ml of the culture were pelleted (2min@15000g@RT) for minipreparation of the 
plasmid DNA. The supernatant was removed with a vacuum pump and cells were 
resuspended in 300µl buffer P1 (50mM Tris-HCl, 10mM EDTA, 100µg/ml RNase 
A, pH8.0). 300µl buffer P2 (200mM NaOH, 1%SDS) were added and tubes were 
inverted 5x. After 1min incubation at RT 300µl buffer P3 (2.8M KAc, pH5.1) were 
added, and tubes were inverted 5x and incubated 1min at RT. Samples were 
then centrifuged for 10min at 15000g at RT. 800µl of the supernatant were mixed 
with 600µl isopropanol in a fresh tube and homogenized by shaking vigorously. 
Precipitated plasmid DNA was pelleted by centrifuging 15min at 15000g at RT. 
The supernatant was removed and the pellet washed once with 500µl 70% EtOH. 
After washing the plasmid DNA was dissolved in 50µl dH2O. 
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The miniprep DNA was then digested with appropriate restriction enzymes to 
identify positive clones: 
 
Component Amount 
10x restriction buffer 1µl 
Miniprep DNA 1µl 
Restriction enzyme (4-20U/µl) 0.2µl  
dH2O Ad 10µl 
 
 
2.5 Tissue culture 
HEK293T and MEF cells were cultured in DMEM supplemented with 10% FCS, 
1% P/S and 1% L-Glu (PAA). Huh7 cells were cultured in DMEM supplemented 
with 10% FCS, 1% P/S, 1% L-Glu and 1% NEAA (PAA). All cells were cultured 
under standard growth conditions (5%CO2, 37°C) and passaged upon 
confluency. For passaging, the growth media was removed, cells were washed 
once with sterile 1xPBS (PAA) and trypsinized by addition of 0.25% trypsin 
(PAA). After detachment of the cells (typically 2-5min depending on the cell type) 
an appropriate amount of growth media was added followed by thorough 
resuspension of the cells by pipetting up and down. A part of the suspension was 
then either discarded or used for subsequent plating and the remaining cells were 
provided with fresh media. 
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2.6 Transfection of mammalian cells 
2.6.1 PEI 
In this study, HEK293T cells were grown to 70-90% confluency and transfected 
using the PEI transfection method. The following table shows the transfection 
conditions for different plate formats: 
 
Plate 
format 
96-well (/well) 24-well (/well) 6-well (/well) 144mm dish 
Cell 
density 
2x104* 1x105* 5x105* 5x106** 
DNA 
amount 
50-200ng 400-800ng 3-3.6µg 44.1µg 
DNA mix 3µl DNA 
3µl NaCl, 
300mM 
12µl DNA 
12µl NaCl, 
300mM 
50µl DNA 
50µl NaCl, 
300mM 
790µl DNA 
790µl NaCl, 
300mM 
PEI mix 3µl NaCl, 
300mM 
1.7µl dH2O 
1.3µl PEI*** 
12µl NaCl, 
300mM 
6.8µl dH2O 
5.2µl PEI*** 
50µl NaCl, 
300mM 
28µl dH2O 
22µl PEI*** 
790µl NaCl, 
300mM 
438µl dH2O 
352µl PEI*** 
*Seeded the day before transfection 
**Seeded two days before transfection 
***linear PEI (MW 25000, PolyScience Inc.) was subjected to 4 freeze-thaw 
cycles and stored at -80°C before use. 
 
The DNA mix was combined with the PEI mix and incubated for 10min at RT. The 
entire solution was then added dropwise directly onto the cells. 
2.6.2 Lipofectamine 2000 
Huh7 cells and MEF cells were grown to 90-95% confluency and transfected 
using Lipofectamine 2000 (Invitrogen). 96-well transfections were done as 
follows: 
 
Cell type Huh7 MEF 2G8 Dicer 
-/- 
MEF IC1 WT 
Cell density 1-1.2x104* 5x103* 6x103* 
DNA amount 50-200ng 200ng 200ng 
DNA mix <5µl DNA 
25µl DMEM 
<5µl DNA 
25µl DMEM 
<5µl DNA 
25µl DMEM 
Lipofectamine 
mix 
0.5µl 
Lipofectamine 
25µl DMEM 
0.5µl 
Lipofectamine 
25µl DMEM 
0.5µl 
Lipofectamine 
25µl DMEM 
*Seeded the day before transfection 
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First, the Lipofectamine was mixed with DMEM and incubated for 5min at RT. 
Subsequently, the Lipofectamine mix was added to the DNA mix and incubated 
for 30min at RT. The entire solution was then added to the cells. 
 
2.7 Dual luciferase knockdown assay 
Cells were grown in transparent 96-well tissue culture plates (Greiner). In 
general, 2.5-5ng (HEK293T) or 50ng (Huh7, MEF) psiCheck-2 vector and 50-
100ng shRNA or TuD vector were used if not stated otherwise. When the TuD 
was delivered in trans shRNA and TuD were transfected at a 1:1 ratio if not 
stated otherwise. Two days post-transfection, the media was removed from each 
well and cells were subsequently lysed in 25µl lysis buffer provided with the 
DualLuciferase assay kit (Promega) and incubated for 15min at RT. 5µl of the 
lysate were transferred into a white LIA plate. Renilla and Firefly luciferase 
activities were measured after consecutive injection of 25µl reconstituted 
luciferase assay buffer and Stop&Glow solution supplemented with Rluc 
substrate according to the DualLuciferase kit using a Glomax 96 microplate 
luminometer (Promega). All data analyses were performed with Microsoft Excel. 
In brief, for each well Rluc values were first normalized to the corresponding Fluc 
values. Subsequently shRNA containing samples were normalized to their 
respective non-silencing controls and plotted. All plots are mean values of several 
experiments (2-4 repetitions in duplicates or triplicates). Exceptions: Fig. 4B, 7B, 
10B, 10C and 20C show representative examples of at least two experiments. 
The random target screen in Fig. 7A was only conducted once. Error bars 
represent the standard deviation. 
 
2.8 GFP reporter assays 
For GFP knockdown assays shown in Fig. 12, HEK293T cells were grown in 24-
well plates (Greiner) and transfected with 500ng shRNA vector and 100ng 
pSSV9-DualFluor vector per well. Two days post-transfection cells were either 
analyzed by fluorescence microscopy or by FACS. For GFP target titration shown 
in Fig. 22, HEK293T cells were grown in a 96-well plate (Greiner) and transfected 
with 100ng of H1-shHCV318 plasmid and 2.5ng, 10ng, 40ng and 100ng of 
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pSSV9-DualFluor reporters carrying perfect binding sites for either the 5’ (sense) 
or 3’ (antisense) strand of shHCV318. 
2.8.1 Fluorescence microscopy 
Cells were not fixed with PFA and stained with DAPI as mCherry signals allowed 
visualization of all transfected cells and were strong enough to permit proper 
autofocusing. Fluorescence images were acquired with an Olympus IX61 
microscope (10x objective; exposure times: 50ms for mCherry and 100ms for 
eGFP; 100% light intensity). Pictures were colored and merged using ImageJ.  
2.8.2 Dual color FACS 
For FACS, cells were trypsinized and washed once with 1xPBS and then kept in 
1xPBS on ice. Analysis was done with a FACScalibur device (BD Bioscience). 
Instrument settings were as follows: Detector gain: FSC, E0 (lin); SSC, 454 (lin); 
GFP (FL-2), 425 (log); mCherry (FL-3), 535 (log). Compensation: FL-3 = 99% FL-
2. Thresholds: primary parameter, FSC; secondary parameter, none. Per sample 
at least 10000 cells were analyzed. Live cells were selected via FSC/SSC. Of 
these, mCherry positive cells were gated such that no naïve HEK293T cells not 
expressing either mCherry or eGFP were detected. Mean values of eGFP signals 
and mCherry signals were quantified only for the mCherry positive cell 
populations. The gating strategy used is illustrated in Suppl.Fig.2. For the two 
perfect targets three and for the mismatch sense strand target two independent 
experiments were conducted. The plot in Fig. 12C represents the mean of the 
repetitions and standard deviation.  
 
2.9 rAAV production 
2.9.1 Iodixanol gradient 
Two days prior to transfection, HEK293T cells were seeded in 144mm tissue 
culture dishes (Nunc) at a density of 5x106 per dish and left to grow for two days. 
For rAAV preparations between 5 and 15 dishes were used per construct and 
purification was achieved by Iodixanol gradient ultracentrifugation. The cells were 
triple-transfected with 14.7µg each of pVAE2AE4-5 (Adeno helper plasmid, 
Matsushita et al., 1998), an AAV-helper plasmid (Whc2 for in vitro transduction 
assays) and the AAV genome plasmid (as indicated) using the PEI transfection 
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method. For a list of produced vectors please refer to Tab. 2. Three days post-
transfection, cells were harvested using a cell scraper, washed once in PBS and 
resuspended in 0.5ml Virus lysis solution (VLS; 50mM Tris, pH8.5, 150mM NaCl). 
Cells were disrupted by three cycles of freezing at -80°C and thawing in a 37°C 
water bath. Samples were sonicated for 1min 20sec to further free the virus from 
the cellular debris. Free nucleic acids were removed by addition of 50U/ml 
Benzonase and incubation at 37°C for 30min while vortexing every 10min. The 
volume was subsequently adjusted to 7ml by addition of VLS. The samples were 
centrifuged for 15min at 5000g at 4°C, and the supernatant was transferred to a 
fresh tube and centrifuged again as before. For generation of the gradient, a 
clean Pasteur pipette was plugged into an ultracentrifuge tube (Re-seal, 
16x76mm, Seton). The virus-containing solution was filled into the tube through 
the Pasteur pipette, followed by 1.5ml of 15% Iodixanole (Optiprep, 60% in PBS-
MK, Sigma) in PBS-MK-NaCl (1xPBS, 1mM MgCl2, 2.5mM KCl, 1M NaCl), 1.5ml 
25% Iodixanol in PBS-MK and 0.5% Phenolred, 1.5ml 40% Iodixanol in PBS-MK 
and finally 60% Iodixanol and 0.25% Phenolred. The Pasteur pipette was 
removed and the centrifuge tubes were filled with VLS until the neck and heat 
sealed using a Beckman tube sealer. Tubes were counterbalanced to a 
difference <0.01g and subjected to ultracentrifugation for 2h at 50000rpm at 4°C 
in a Beckman 70.1Ti rotor. After the run the virus-containing 40% Iodixanol phase 
was pulled from the gradient using a syringe and frozen at -80°C in aliquots the 
same day. 
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2.9.2 rAAV vector titration 
10µl of each rAAV preparation were mixed with 10µl TE buffer (1mM Tris-HCl, 
0.01mM EDTA pH8.0) and 20µl 2M NaOH prior to incubation for 30min at 56°C 
for lysis of the viral capsid. After neutralization with 39µl 1M HCl the volume was 
adjusted to 1ml with dH2O. Genomic titers were subsequently determined by 
qPCR with the probes and primers as indicated in Tab. 1. 
 
Component Per triplex 
2x Sensimix II Probe Mix 
(Bioline) 
17.5µl 
Forward primer (10µM) 1.4µl 
Reverse primer (10µM) 1.4µl 
Probe (10µM) 0.35µl 
Nuclease-free water 9.35µl 
Sample/standard 5µl 
Total 35µl 
Cycling conditions: 
10min, 95°C 
40 cycles of 
10s, 95°C 
20s, 60°C 
 
The number of rAAV genome molecules was determined by a plasmid standard 
run in parallel.  
 
Target Probe (5‘?3‘) 5’ primer (5‘?3‘) 3‘ primer (5‘?3‘) 
EGFP FAM-ACGACGGCAACTACA-BHQ1 GAGCGCACCATCTTCTTCAAG TGTCGCCCTCGAACTTCAC 
CMV FAM‐AGTCATCGCTATTACCATGG
‐BHQ1 
TGCCCAGTACATGACCTTATGG GAAATCCCCGTGAGTCAAA
CC 
Tab. 1: Real-time PCR primers and fluorescently labeled probes used for rAAV vector 
titrations. 
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# Construct Used for
1 H1-shHCV318-CMV-empty 
 
‐ Reporter assays in HEK293T and Huh7 cells 
‐ HCV inhibition assays 
2 H1-shHCV318-CMV-HCV318 
 
‐ Reporter assays in HEK293T and Huh7 cells 
‐ HCV inhibition assays 
3 H1-CMV-empty 
 
‐ Reporter assays in HEK293T and Huh7 cells 
‐ HCV inhibition assays 
4 H1-H1-TuD-empty ‐ Reporter assays in Huh7 cells 
‐ Expression profiling in Huh7 
5 H1-shHCV318-H1-TuD-empty 
 
 
‐ Reporter assays in HEK293T and Huh7 cells 
‐ HCV inhibition assays 
‐ Expression profiling in Huh7 
6 H1-shHCV318-H1-TuD-HCV318 
 
 
‐ Reporter assays in HEK293T and Huh7 cells 
‐ HCV inhibition assays 
‐ Expression profiling in Huh7 
7 H1-H1-TuD-HCV318 
 
 
‐ Reporter assays in HEK293T and Huh7 cells 
‐ HCV inhibition assays 
‐ Expression profiling in Huh7 
8 H1-hAAT25-H1-TuD-empty ‐ Reporter assays in Huh7 cells 
9 H1-hAAT25-H1-TuD-hAAT ‐ Reporter assays in Huh7 cells 
10 H1-hAAT25-U6-TuD-empty ‐ Reporter assays in Huh7 cells 
11 H1-hAAT25-U6-TuD-hAAT ‐ Reporter assays in Huh7 cells 
12 H1-U6-TuD-hAAT ‐ Reporter assays in Huh7 cells 
13 H1-shHBVS122nt-U6-TuD-empty ‐ Reporter assays in Huh7 cells 
14 H1-shHBVS122nt-U6-TuD-HBVS1 ‐ Reporter assays in Huh7 cells 
15 H1-U6-TuD-HBVS1 ‐ Reporter assays in Huh7 cells 
16 H1-TuD-M122-GFP* ‐ HCV inhibition assay 
17 H1-TuD-HCV318-GFP* ‐ HCV inhibition assay 
Tab. 2: Vectors produced during the course of this study. All vector were packaged into 
AAV2 capsids and purified by Iodixanol gradient centrifugation. * produced by N. 
Schürmann. 
 
2.10 HCV inhibition assay 
Huh7.5-lucubineo-JFH1 or -ET replicon cell lines were cultured in DMEM 
supplemented with 10% FCS, 1% P/S, 1% L-Glu, 1% NEAA and 1mg/ml or 
500µg/ml G418, respectively. On the day of infection, 1x106 cells were seeded 
per 96-well plate and infected at an MOI of 103, 104 or 105 directly thereafter. Two 
days post-infection, the growth media was removed, cells were lysed in 30µl Fluc 
lysis buffer (0.1% Triton X-100, 25mM glycylglycin, pH7.8, 15mM MgSO4, 4mM 
EGTA, pH7.8, 10% glycerol, 1mM DTT) per well and immediately frozen at -
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20°C. After thawing, 20µl of lysate were transferred to white LIA plate, 50µl of 
Fluc assay buffer (25mM glycylglycin, 15mM KPO4, pH7.8, 15mM MgSO4, 4mM 
EGTA, 7µM D-luciferin, 2mM ATP, 1mM DTT) were added and incubated for 
15min at room temperature in the dark. Fluc activity was measured using a 
Glomax 96 microplate luminometer (Promega). The HCV inhibition assay with 
TuD-miR-122-5p was conducted by N. Schürmann. 
 
2.11 Expression profiling by microarray 
2x105 Huh7 cells were seeded per well in a 6-well plate. The next day the cells 
were transduced at an MOI of 105 with the different shRNA/TuD rAAV2 vectors. 
Two days post-infection the cells were lysed and total RNA was prepared using 
Qiazol (QIAGEN) according to the manufacturer’s instructions. Quality of the 
RNA was checked by Bioanalyzer (Agilent) using a RNA Nano Chip (Agilent). All 
RNA integrity numbers (RINs) were at least 8.7. The samples were then analyzed 
with a HumanHT-12 v4 Expression BeadChip (Illumina). Reverse transcription, 
hybridization and data normalization to reference transcripts were conducted by 
the DKFZ genomics core facility. For analysis of the results all transcripts whose 
expression was less than 3-fold higher than their standard deviation were 
excluded (background subtraction). Dysregulated transcripts were identified by 
comparison of either shRNA sample with the NSC (T-test, unpaired, two-sided, 
p<0.01, DF=14). Genes that were significantly less dysregulated in one shRNA 
sample than in the other were determined by comparing the two shRNA samples 
against each other (T-test, unpaired, two-sided, p<0.01). The respective genes 
were grouped as indicated in Fig. 15 and the 3’ UTR sequences of each group 
were extracted from the Ensembl database using the HGNC gene symbols in the 
Biomart tool without any further specifications (see section 6.2 for weblink; 
sequence retrieval, 3’ UTR). Not all genes on the chip had extractable 3’ UTR 
sequences so that the number of genes used for seed match analysis was 
slightly lower than the total number of significant hits. For analysis of sequence 
enrichment in each gene group, the appearances of each of the indicated 
sequences in the 3’ UTRs were counted and the frequency per gene was 
calculated by dividing the count by the number of genes in the respective group. 
All genes with extractable 3’ UTR sequences present on the chip were used as 
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background set. Statistical significance of the counting results was determined by 
Fisher’s exact test (in Group 1: one-sided test for sense strand seed matches; 
two-sided test for antisense strand seed matches; in Group 2: two-sided test for 
sense strand seed matches; one-sided test for antisense strand seed matches). 
Levels of significance are only given if p<0.05. 
Experimentally validated target genes for miR-122-5p, miR-16-5p, miR-21-5p, 
miR-22-3p, miR-24-3p, miR-130a-3p and miR-192-5p were identified via the 
tarbase database (Vergoulis et al., 2012; see section 6.2 for weblink). The genes 
selected for analysis are indicated in Tab. 3. The relative expression of these 
targets was plotted for each of the two shRNA samples. 
 
miRNA HGNC symbols of analyzed target genes 
miR-122-5p BCL2L2, CCNG1, IGF1R, CDK4, TRPV6, BCL2L1, HMOX1, BAX, 
NCAM1, G6PC3, GYS1, SRF, CALU, OSBP2, HSPA5, KRT18, 
C21orf34, BRI3BP, PSPH, EIF2S1, DDIT3, CHST12, C20orf3, 
ALDOA3, ALDOA2 
miR-16-5p BCL2a, BCL2b, ARL2, CCNT2, TPPP3, VEGFA, CCND1, RARS, 
PURA, PNPLA6, CA12, TMEM43, PISD, ZNF622, YIF1B, 
FNDC3B, ITGA2, FGF2, SHOC2, ATG9A 
miR-21-5p SERPINB1, PTEN, PDCD4, RECK, PPARA, TIMP3, TPM1, 
TGFBR2, CDK2AP1, VEGFA, BCL2a, BCL2b 
miR-22-3p ACVR1C, SP1, CCNT2, E2F2, BTF3, TBX3, TBC1D12, CDK6, 
SFRS7, LEMD3, FRAT2, FOXP1, C14ORF106, C20ORF117 
miR-24-3p FEN1, CDK4, CCNA2, CDC2, AURKB, HNF4A, MYC, PCNA, 
CHEK1, BRCA1, ACVR1B, MAPK14, CDKN2A, MLEC 
miR-130a-3p MEOX2, HOXA5, TAC1, ZFPM2, APP, ATXN1, MAFB, CSF1, 
HOXA10, KLF4 
miR-192-5p LMNB2, CUL5, CDC7, MAD2L1, PIM1, RACGAP1, SEPT10, DTL, 
ERCC3, BCL2a, BCL2b, DLG5, HRH1, SMARCB1, PRPF38A, 
MIS12 
Tab. 3: List of miRNA target genes that were used for analysis of effects of shHCV318 
expression on the miRNA pathway. 
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2.12 Reverse transcription quantitative PCR (RT-qPCR) 
2x105 Huh7 cells were seeded per well in a 6-well plate. The next day the cells 
were transduced with an MOI of 105 with the different shRNA/TuD rAAV2 vectors 
or left naïve. Two days post-infection the cells were lysed and total RNA was 
prepared using Qiazol (QIAGEN) according to the manufacturer’s instructions. 
DNA was removed from 2µg total RNA by treatment with TurboDNase (Ambion) 
in 20µl reaction volume according to the manufacturer’s guidelines. 10µl (1µg) of 
DNA-free total RNA were carefully transferred to a fresh microfuge tube (DNase 
stop reagent interferes with a subsequent RT-qPCR reaction) and reverse 
transcribed using the Tetro cDNA kit (Bioline) according to the manufacturer’s 
guidelines. The volume of the cDNA samples was brought to 50µl (final cDNA 
concentration was 20ng/µl). The respective genes were quantified using the 
Sensimix SYBR no-ROX kit (Bioline) in 10µl reactions according to the 
manufacturer’s guidelines. Expression of each gene was first normalized to 
GAPDH by the deltaCt method and then further normalized to the NSC carrying 
the specific shHCV318 TuD. The primers were used for amplification are 
indicated in Tab. 4 (GAPDH primers were as previously published; all other 
primers obtained from PrimerBank database (see section 6.2 for weblink). 
 
Gene name 
(HGNC symbol) 
FWD primer (5’?3’) REV primer (5’?3’) 
GAPDH GAAGGTGAAGGTCGGAGTC GAAGATGGTGATGGGATTTC 
CIRBP AATGGGAAGTCTGTAGATGGACG CGGGATCGGTTGTCTGACG 
SEPT9 GTCCATCACGCACGATATTGA TGCAGGTATTTCTCGTACTGGT 
RAN CTCTGGCTTGCTAGGAAGCTC GCAACAAATTCCAAGTTAGGGTC
Tab. 4: List of primers used for RT-qPCR analysis. 
 
2.13 Small RNA Northern blot 
2x105 Huh7 or 5x105 HEK293T cells were seeded per well in a 6-well plate. The 
next day the cells were transduced with an MOI of 105 with the different 
shRNA/TuD rAAV2 vectors (Huh7) or transfected with 3µg of shRNA expressing 
plasmids (HEK293T). Two days post-infection or -transfection the cells were 
lysed and total RNA was prepared using Qiazol (QIAGEN) according to the 
manufacturer’s instructions. 6µg (for miR-122-5p detection in Huh7 cells), 10µg 
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(for shRNA and TuD detection in Huh7 cells) or 15µg (for shRNA detection in 
HEK293T cells) of total RNA were mixed with 3xRNA loading buffer (8M Urea, 1X 
TBE, 30 mM EDTA, 20% glycerol, dyes: BPB & XC), briefly denatured at 80°C 
and resolved in a 12% acrylamid / 8M urea gel in 1XTBE in a Protean running 
chamber (Biorad). In case the total volume of RNA and loading buffer exceeded 
10µl, the RNA was first precipitated by addition of 1/10 volume of 3M NaAc, 
pH5.2, and 3 volumes of 100% EtOH and subsequently redissolved in 5µl 
nuclease-free dH2O. The RNA was then electroblotted onto a Nylon membrane 
(Hybond N+, Amersham) and UV-crosslinked (time-program, CL-1000 UV 
crosslinker, UVP). For probe generation, 50pmol of an oligonucleotide were end-
labeled by T4-PNK (NEB) for 30min at 37°C using 25µCi of [gamma-32P]ATP 
under standard reaction conditions. The Nylon membrane was cut into the 
desired pieces, pre-hybridized in PerfectHyb hybridization buffer (Sigma) at 37°C 
for 30min and hybridized overnight with appropriate radioactively labeled probes 
at 37°C. Subsequently the membrane was washed with 2xSSPE/0.1%SDS 
(300mM NaCl, 25mM NaH2PO4, 2mM EDTA, 0.1% SDS, pH7.4) twice at 37°C 
(high stringency) and twice at room temp (low stringency) followed by exposure 
to phosphorimager screens for an appropriate period of time. A list of DNA 
probes used for small RNA Northern blot is given in Tab. 5. 
 
 
Probe target Probe sequence 
U6 snRNA TGTGCTGCCGAAGCGAGCAC 
shHCV318 antisense strand TCGAGGGAGGTCTCGTAGACCGTGCA 
shHCV318 sense strand TCGATGCACGGTCTACGAGACCTCCC 
TuD-HCV318 perfect GGCCGGGAGGTCTCATAGACCGTGCA 
hAAT antisense strand TCGAGAAGCGTTTAGGCATGTTTAACATC 
hAAT sense strand TCGAGATGTTAAACATGCCTAAACGCTTC 
miR-122-5p CAAACACCATTGTCACACTCCA 
Tab. 5: List of DNA probes used for small RNA Northern blot. 
 
2.14 mRNA Northern blot for GFP and mCherry 
5x105 HEK293T cells were seeded per well in a 6-well plate. The next day the 
cells were transfected with 2µg shRNA/TuD expressing plasmids and 200ng 
DualFluor target plasmids. Two days post-transfection the cells were lysed and 
total RNA was prepared using Qiazol (QIAGEN) according to the manufacturer’s 
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instructions. 2µg of total RNA were mixed with 1/3 loading buffer (Ambion), briefly 
denatured at 65°C and resolved in a 0.8% agarose/6.7% formaldehyde gel in 
1XMOPS buffer (Northernmax, Ambion). The RNA was transferred onto a Nylon 
membrane (Hybond N+, Amersham) by passive diffusion overnight and UV 
crosslinked (time-program, CL-1000 UV crosslinker, UVP). For probe generation, 
the EYFP CDS was cut out of pIRESNeo-FLAG/HA-EYFP by BamHI or the 
mCherry CDS was cut out of pSSV9-DualFluor by HindIII/SalI and gel purified. 
50ng template were then used for random priming probe generation using the 
Prime-it Rmt Random priming kit (Stratagene) according to the manufacturer’s 
instructions. The Nylon membrane was pre-hybridized in pre-heated PerfectHyb 
hybridization buffer (Sigma) at 68°C for at least 15min followed by hybridization 
with the EGFP probe for at least 8h at 68°C. The membrane was washed twice in 
2xSSC/0.1% SDS (300mM NaCl, 30mM sodium citrate, 0.1% SDS, pH7.0) at RT 
followed by two washings in 0.1xSSC/0.1% SDS (15mM NaCl, 1.5mM sodium 
citrate, 0.1%SDS, pH7.0) at 68°C. The membrane was subsequently exposed to 
phosphorimager screens for an appropriate period of time. 
RESULTS 
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3 RESULTS 
3.1 shRNA strand activities 
3.1.1 Strand biasing 
It has been reported previously that the sense strand of shRNAs with perfectly 
matched stems could be efficiently inactivated merely by placing it at the 5’ end of 
the hairpin (Boudreau et al., 2008). However, this effect was only shown for a 
limited number of shRNAs. In order to optimize the design of our own RNAi 
triggers we wanted to find out whether this rule could be readily applied to any 
shRNA. We hence measured the activities of both strands of various previously 
published shRNAs and compared them to the data of Boudreau and colleagues. 
Instead of directly comparing absolute silencing efficiencies of each strand we 
suggested that the relative strand activity (RSA) would be a better parameter for 
proper comparison. The RSA is a direct measure to evaluate the degree of strand 
biasing of shRNAs. It is calculated as activity of the antisense strand on a perfect 
match target divided by the activity of the sense strand on a perfect match target 
(Fig. 4A). Ideally, the RSA of an shRNA should be as high as possible meaning 
maximal activity of the antisense strand which is desired for silencing of the 
designated target of the shRNA and minimal activity of the sense strand.  
We hence transfected HEK293T cells with a set of 11 shRNAs with varying stem 
lengths that were directed against 4 different targets along with luciferase 
reporters carrying perfect targets for either strand and measured relative 
luciferase activities 48h post-transfection. Sequences of all shRNAs and targets 
can be found in Suppl.Tab.1. As expected, we observed highly efficient silencing 
of the antisense strand target for all shRNAs (Fig. 4B). However, also the sense 
strands of all shRNAs yielded knockdown of their respective targets. Some of the 
shRNAs had their sense strand at the 5’ and some at the 3’ end (Suppl.Tab.1). 
For those shRNAs with stems ≥21nt we noticed a clear tendency towards higher 
activity of the 3’ strand leading either to RSAs above or below 1 depending on the 
position of the sense strand. This correlates with the data of Boudreau and 
colleagues where all three shRNAs with strong strand bias had stems longer than 
21nt. However, the RSAs measured here were highly variable (between 1.3 and 
6.7 for those shRNAs with the sense strand at the 5’ end) and for the majority of 
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our shRNAs lower than what had been reported previously (around 6-8 as 
estimated from Boudreau et al., 2008). 
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3.1.2 Concentration dependency of relative strand activities 
To obtain further insights into the expression kinetics of both shRNA strands we 
next assessed the concentration dependency of the RSA. For this experiment, 
we selected two shRNAs targeting the same sequence in human-alpha-1-
antitrypsin (hAAT) with either a 19-mer (hAAT19) or 25-mer (hAAT25) stem 
which allowed us to examine the influence of the stem length. These shRNAs 
have their antisense strand at the 3’ end and sense strand at the 5’ end. For 
hAAT19 both strands had shown equal activities in the previous assay (RSA=1) 
and hAAT25 had an intermediate bias towards the 3’ strand (RSA=1.9). We 
transfected HEK293T cells with varying amounts of shRNA plasmids and 
measured activity of both strands by dual luciferase assay. We found that the 
RSA varied between the different plasmid doses for both shRNAs and was 
generally best at low amounts (Fig. 4C+D). The 3’ strand hence appears to reach 
near-maximal levels of activity at lower concentrations than the 5’ strand. The 
degree of strand biasing was considerably different between the short and the 
long version. At 0.4ng, the antisense strand was over 6-fold more active than the 
sense strand for hAAT25 but below 2-fold more active for hAAT19. We also 
observed that the absolute potency of the antisense strand was higher with the 
25-mer than with the 19-mer shRNA which is in agreement with previous reports 
(Siolas et al., 2005). It is important to note that for both shRNAs the activity ratio 
declined when the shRNA concentration was too low. Thus, there seems to be a 
certain window of shRNA concentration where the RSA is optimal. We next 
assessed the expression levels of the two strands after HEK293T transfection by 
Northern blot under conditions with optimal RSA. The sense strands of both 
shRNAs were expressed at comparable levels whereas the antisense strand of 
hAAT25 was much higher expressed than the hAAT19 antisense strand (Fig. 
4E). This confirms that there is indeed a bias towards maturation of the 3’ strand 
for hAAT25 but not hAAT19. We next conducted similar functional analyses with 
another shRNA pair of 19 or 25nt in length, i.e. sAg19 and sAg25, that have an 
inverted strand order as compared to the hAAT shRNAs. Their sense strand is 
therefore located at the 3’ end and the antisense strand at the 5’ end (Suppl.Fig. 
1). Despite the structural similarity between the two shRNA pairs the results for 
sAg19 and -25 were fundamentally different to what had been measured for 
hAAT19 and -25. We found a bias towards the 5’ antisense strand for sAg19 
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(RSA up to 1.6) and a slight preference for the 3’ sense strand for sAg25 (RSA 
down to 0.8) and no clear concentration dependency. A similar finding for both 
shRNA pairs was a more pronounced bias towards the 3’ strand for the 25-mer 
as compared to the 19-mer. The functional strand bias thus seems to depend 
both on shRNA sequence and stem length. From our data we conclude that 
shRNAs are best designed to have the sense strand at the 5’ end and stems of 
21 nucleotides or longer. However, this design does not appear to guarantee 
sense strand inactivation to negligible levels for all shRNAs. 
3.1.3 3’ but not 5’ strand activity requires Dicer 
Apart from functionally testing the two shRNA strands we also wanted to gain 
insight into the mechanism of the observed strand bias. It has been shown 
previously that in in vitro Dicer assays 25-mer shRNAs were readily processed by 
Dicer whereas a corresponding 19-mer shRNA was not (Siolas et al., 2004). This 
finding seems logical in light of other studies reporting that the typical Dicer 
processing product is 22nt in length so that intuitively an shRNA with only 19nt 
stem length will be difficult to dice (Zhang et al., 2002). It has also been 
demonstrated that Dicer substrate duplex RNAs have a significant bias towards 
the strand that is bound by Dicer which in case of shRNAs can only be the 3‘ 
strand via its 2nt 3‘ overhang (Rose et al., 2005). The strong functional strand 
bias of hAAT25 that was not found with hAAT19 could thus be linked to Dicer. 
Consequently, we wanted to correlate our results on relative strand activities with 
Dicer processing. To this end, we conducted luciferase knockdown experiments 
in MEF WT and Dicer-/- cells and tested the activity of both strands with hAAT 
shRNAs of different stem lengths. Along with the aforementioned hAAT19 and -
25 we also used hAAT21 and hAAT23 with respective stem lengths of 21 or 23nt. 
According to Siolas and colleagues we expected both strands to be Dicer-
dependent for hAAT21-25 and both strands Dicer-independent for hAAT19 in this 
system (Siolas et al., 2004). However, our results clearly show that the activity of 
the 3‘ but not the 5’ strand depends on the presence of Dicer in the cells, 
regardless of shRNA stem length (Fig. 5A+B). We thus did not see any direct 
correlation between Dicer processing and the functional strand bias as we had 
previously expected. Thereby, these results show for the first time that the two 
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strands of both short and long shRNAs with perfect stems rely on different 
principles of maturation. 
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Fig. 5: 3‘ but not 5‘ strand activity depends on Dicer regardless of shRNA stem length.
A-B: MEF WT or Dicer -/- cells were transfected with hAAT shRNAs with indicated stem
lengths. 48h post-transfection, either 3‘ strand (A) or 5‘ strand (B) activity was determined by
dual luciferase assay. RLU=relative light units; NSC=non-silencing control.
hAAT
Dicer WT -/- WT -/- WT -/- WT -/- WT -/- WT -/- WT -/- WT -/-
19 21 23 25 19 21 23 25
3' strand target 5' strand target
†
† NSC in either MEF WT or Dicer -/- cells
hAAT
Dicer
†
† NSC in either MEF WT or Dicer -/- cells
†
†
 
 
3.2 shRNA sense strand counteraction by RNA-pol II sponges 
A previous study reported four different conserved sites in the HCV 5’NTR that 
were susceptible to shRNA-mediated silencing of HCV replication (Krönke et al., 
2004). For our subsequent analyses we generated an shRNA against the target 
site that allowed the highest degree of HCV inhibition. The original shRNA 
described by Krönke and colleagues had a 19-mer stem. In order to apply the 
design that we had determined in section 3.1 we added 3nt to the 5’ end of the 
shRNA to increase the stem length above 20nt and termed it shHCV318. As 
previous reports showed deleterious side effects (see section 1.1.7.2) of U6-
driven shRNAs we decided to use the weaker H1 promoter for shHCV318 
expression. Due to the nature of this particular target site the antisense strand of 
the shRNA also has a seed that can be considered “safe” (see section 1.1.7.1). 
The number of hexamer matches to this seed in human 3’ UTRs is considerably 
lower than that of other hexamers (cf. Fig. 16B+C, note that the frequency of 
antisense seed matches in the background set are much lower those of the 
sense strand seed). This is presumably due to the presence of a CG dinucleotide 
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that has a relatively low frequency in the human genome (cf. Fig. 16A; Anderson 
et al., 2008).  
To determine the relative strand activities of shHCV318 we measured sense and 
antisense activity by perfect match target reporters. Upon transfection of 
HEK293T cells shHCV318 produced potent knockdown from both strands with a 
minor bias towards the antisense strand located at the shRNA 3’ end (Fig. 6A). 
This finding confirmed that the sense strand of shRNAs can be highly active even 
if the shRNA sequence is in agreement with state-of-the-art design methods.    
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Fig. 6: shHCV318 strand activities and sense strand counteraction by inhibitor
transcripts. A: HEK293T cells were transfected with shHCV318 and perfect target reporters
for sense or antisense strands. 48h post-transfection strand activities were measured by dual
luciferase assay. B: In principle, both strands of an shRNA can be active as RNAi trigger. By
co-expressing an inhibitor RNA transcript carrying specif ic binding sites for the sense but not
the antisense strand, activity of the sense strand could be selectively reduced without affecting
the silencing potential of the antisense strand. RLU=relative light units; NSC=non-silencing
control.
Sense strand
Antisense strand
5‘
3‘
3‘5‘
5‘3‘
5‘ 3‘
Normal strand activity
Reduced strand
activity
shHCV318
Inhibitor RNA
Sense strand binding site
A B
shHCV318
NSC
A
nt
is
en
se
 
ta
rg
et
S
en
se
 
ta
rg
et
 
 
As shRNA sense strand activity appeared to play a more important role than 
initially expected, we decided to devise a novel strategy to improve the RSA of 
shRNAs by selectively decreasing sense strand activity with shHCV318 as 
example. Our approach is based on co-expression of an inhibitor RNA transcript 
that sequesters and selectively inactivates the sense strand without disturbing 
antisense-mediated silencing (Fig. 6B). In principle, the modular design of the 
proposed system should be advantageous as it should allow increasing 
specificity without the need to alter shRNA design algorithms and facile 
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implementation for already existing or new shRNAs. The same principle -i.e. 
quantitative sequestration- had already been reported for the inhibition of 
miRNAs where both RNA-pol II and RNA-pol III transcripts have been 
successfully used in different settings (Ebert and Sharp, 2010). In this context, 
RNA-pol II transcripts are called „sponges“, whereas RNA-pol III transcripts are 
termed „decoys“. Since we could not predict which transcript class would be best 
suited for our strategy, we commenced with RNA-pol II „sponge“ constructs that 
had been first described in 2007 (Ebert et al., 2007). These sponges consist of an 
mRNA -in our case encoding eGFP- containing one or more binding sites for the 
respective RNAi trigger. 
3.2.1 Binding sites with single central mismatches are high affinity shRNA 
targets 
In the original publication Ebert and colleagues showed that imperfect target sites 
-i.e. non-slicer substrates- with triple central mismatches to the targeted miRNA 
yielded better sponge efficiencies than perfect target sites that are sliced upon 
RISC binding. Thus, to select an ideal binding site for sponge construction, we 
first tested a binding site with a triple mismatch to the sense strand of shHCV318. 
However, this binding site showed only little responsiveness when cloned into the 
3’ UTR of a luciferase reporter so that it could not be used for shHCV318 sponge 
construction (Fig. 7B). Triple mismatch sites for the sense strands of hAAT and 
sAg shRNAs were found not to be functional, either (data not shown). As miRNAs 
can efficiently silence targets with triple central mismatches our results indicate 
that shRNAs seem to have somewhat different target sequence requirements. 
We therefore decided to conduct a random target screen to identify mismatched 
target sites that would allow shRNA sense strand binding with maximal potency 
and that could subsequently be used for sponge generation. To get a general 
idea about shRNA target requirements we first conducted the screen for hAAT 
and then applied the identified target design to shHCV318. To this end, we 
cloned luciferase constructs carrying target sites for the sense strand of hAAT19 
and hAAT25 (the sense strands of which are similar) with randomized 
nucleotides at positions 10-12. By this means the majority of the resulting 
sequences had between 1 and 3 mismatches at these positions and could not be 
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sliced as the slicing reaction takes place between nt 10 and 11 (Martinez et al., 
2002).  
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Fig. 7: Random target screen for identification
of efficient shRNA target sites. A: Targets for the
hAAT shRNA sense strand with randomized
nucleotides at positions 10-12 were cloned into the
Rluc 3' UTR. 89 clones were picked and co-
expressed with hAAT19 or NSC in HEK293T cells
and luciferase knockdown was measured 48h post-
transfection. 20 clones that permitted best silencing
including a perfect match control were tested in a
second round of knockdown measurement. The
target sites of the indicated clones were sequenced.
Shown are the alignments to the perfect match
target. B: shHCV318 was co-transfected with sense
strand target reporters with either perfect
complementarity or a single mismatch at position 11
or a triple mismatch at positions 10-12. Luciferase
knockdown was measured 48h post-transfection.
RLU=relative light units; NSC=non-silencing control.
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We picked 89 different clones and tested them for susceptibility to silencing 
mediated by the hAAT19 sense strand (Fig. 7A). After a first round of luciferase 
expression screening we repeated the assay with 20 clones that permitted 
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strongest knockdown including a perfect match control. After the second round of 
measurement we sequenced the binding sites of 8 clones to determine the 
sequence requirements for efficient sense strand binding (Fig. 7A). We found that 
the most potent sites had single mismatches at either position 10 or 11 as 
counted from the 5’ end of the shRNA sense strand with the exception of clone 
H6 that had a double mismatch. One clone -C8- had an additional mismatch at 
the 3’ nucleotide which did not appear to influence its affinity to the shRNA sense 
strand. Clone C9 that was less susceptible to silencing carried a triple mismatch. 
Clone E1 that behaved like the perfect match control that we had included in the 
assay indeed carried a perfectly complementary target site, thus proving the 
validity of our results. Our data therefore suggested that binding sites with single 
mismatches at either position 10 or 11 are best suited for sponge construction. 
We next determined whether this design could be applied to the sense strand of 
shHCV318. We cloned a target with a single mismatch at position 11 into the 3’ 
UTR of Rluc and examined knockdown efficiencies in comparison to the perfect 
target and the triple mismatch target tested initially. The single mismatch target 
was efficiently silenced by the shHCV318 sense strand indicating that it should 
be well suited for subsequent construction of the sponge (Fig. 7B).  
3.2.2 A sponge efficiently counteracts the shHCV318 sense strand upon 
transfection 
In the next step, we used the single mismatch target site to generate a sponge for 
the sense strand of shHCV318. We constructed a bicistronic vector carrying both 
the H1-shRNA and a CMV-transcribed sponge (Fig. 8A). The whole insert is 
flanked by AAV ITRs that allow direct packaging into AAV particles. We first 
transfected HEK293T cells with shHCV318 and a control or a specific sense 
strand sponge and perfect target reporters for both shRNA strands. The sense 
strand sponge successfully counteracted shHCV318 sense strand activity ~3.5-
fold (Fig. 8B). The desired antisense strand activity was not disturbed by the 
sponge proving that our concept of selective sense strand inhibition worked.  
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Fig. 8: Efficient sense strand inhibition via
RNA-pol II sponges after plasmid
transfection. A: Schematic representation of
the vector constructs carrying both an shRNA
and a sponge expression cassette. The
shHCV318 sense strand target site was
inserted in the 3' UTR of eGFP. The insert is
f lanked by an AAV2 ITR and a mutated AAV4
ITR which permits packaging as self -
complementary rAAV. B: HEK293T cells
were transfected with shHCV318, a reporter
for either strand and a control or specific
sense strand sponge. Reporter knockdown
was measured 48h post-transfection by dual
luciferase assay. RLU=relative light units.
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3.2.3 Translation of the sponge into an rAAV context 
To improve the applicability of the approach we next tested the compatibility with 
rAAV-mediated gene transfer. We hence packaged shHCV318 with either a 
control or a specific sponge into self-complementary rAAV2 particles and tested 
antisense strand activity in an HCV inhibition experiment and sense strand 
activity in a luciferase reporter experiment.  
We used our vectors at different MOIs to transduce Huh7 cells carrying 
subgenomic RNA replicons of different HCV genotypes that encode Firefly 
luciferase (Fluc; Lohmann et al., 1999). Fluc expression correlates with HCV 
replication and could thus be used as an easy means of measuring HCV 
inhibition by shHCV318. Indeed, we observed a strong dose-dependent reduction 
of HCV replication for both HCV genotypes 1b and 2a (Fig. 9A+B). At the highest 
MOI, both genotypes were silenced by around two orders of magnitude. As 
expected, we did not observe any effect of the sense strand sponge on the HCV 
silencing potential of the shRNA.  
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Fig. 9: Translation of RNA-pol II sponge strategy into rAAV2 context. A+B: HCV inhibition
by shHCV318 after transduction of Huh7 cells carrying subgenomic replicons of HCV genotype
1b (A) or 2a (B) at indicated MOIs 48h post-infection. HCV replication was quantif ied by
measurement of Fluc activity encoded by the HCV replicons. C: HEK293T cells were
transduced with rAAV2 (MOI=105) encoding shHCV318 and control or specif ic sponge or a
NSC and co-transfected with luciferase reporters for both strands. Strand activities were
measured by dual luciferase assay af ter 48h. D: Huh7 cells were transduced with rAAV2
(MOI=105), total RNA was extracted 48h post-infection and sHCV318 expression was
analyzed by small RNA Northern blot. Statistical analysis: unpaired, one-sided T-test, * p<0.05.
RLU=relative light units; MOI=multiplicity of infection.
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We next tested counteraction of the sense strand in the rAAV2 context in 
transduced HEK293T cells. Under these conditions, the sponge relieved 
repression of the unintended sense strand target by less than 2-fold with only 
weak statistical significance (Fig. 9C). The effect was hence more than 2-fold less 
pronounced than what we had observed upon HEK293T transfection (cf. Fig. 8B). 
To show that this was not due to differences in functionality of the two rAAV2 
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vectors encoding the shRNA plus control or specific sponge we visualized 
expression of the encoded shHCV318 by Northern blot. The signals of both 
shRNA strands did not differ between the samples meaning that expression from 
either vector was equally efficient (Fig. 9D). However, the functional discrepancy 
between transfection- and transduction-based gene delivery correlated with very 
high eGFP expression levels achieved in HEK293T cells upon transfection and 
considerably lower eGFP expression upon transduction as observed by 
fluorescence microscopy. While the shRNA was equally active upon transfection 
and transduction the sponge appeared to be higher expressed upon transfection 
which could explain the obtained results. 
 
3.3 shRNA sense strand counteraction by RNA-pol III tough 
decoys 
As a major goal of our study was to ultimately utilize rAAVs for delivery of RNAi-
triggers the shHCV318 sponge did not appear to be the best option for our 
strategy for sense strand inhibition. We hence decided to test our approach with 
an RNA-pol III-transcribed decoy as an alternative. From all of the previously 
reported decoy constructs, “tough decoys” (TuDs) as first described by Haraguchi 
et al. in 2009 seemed to be best suited for our approach as they were shown to 
be highly active and yet easy to design (Fig. 10A) (Haraguchi et al., 2009). In 
addition, they are very short and carry no single-stranded RNA stretches except 
for the miRNA -or in our case shRNA- binding sites thus minimizing the risk of 
unintended sequestration of miRNAs or other cellular RNA binding factors which 
is another advantage over the much longer sponge transcripts. 
3.3.1 TuDs efficiently inhibit an shRNA sense strand upon transfection and 
rAAV-mediated transduction  
We generated a TuD transcript against the sense strand of shHCV318 using the 
same imperfect binding site as previously for the sponge. For proof-of-principle, 
we expressed shHCV318 and TuD from separate plasmids and tested both the 
strong U6 and the weaker H1 promoter for TuD expression. We transfected 
HEK293T cells with shHCV318 or a non-silencing control (NSC) either with the 
control TuD without binding sites or the specific TuD carrying sense strand 
targets. With both promoters the specific TuD was able to efficiently counteract 
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the sense strand ~5-fold (Fig. 10B+C). As we did not find any significant 
difference in performance between the two promoters we decided to 
subsequently use the H1 promoter for TuD expression. In addition, the NSCs with 
control or specific TuD did not significantly differ in their behaviors in the reporter 
assays. This allowed us to use the NSC with specific TuD as unique control in 
subsequent experiments.  
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Fig. 10: Specific and efficient
counteraction of shRNA sense strand
activity by RNA-pol III TuDs after
transfection. A: Schematic representation of
tough decoy (TuD) transcripts carrying up to
two sense strand binding sites. B+C:
HEK293T cells were transfected with
shHCV318 and control or specific TuD driven
by H1 (B) or U6 (C) promoters expressed
from separate plasmids. Rluc reporter
silencing was measured 48h post-
transfection. RLU=relative light units.
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We next tested the functionality of the system with shRNA and TuD expressed 
from the same plasmid. We chose a vector design based on the shRNA vector 
described by Grimm et al. in 2006 (Grimm et al., 2006a). Our final constructs 
allow easy de novo cloning of both shRNA and TuD binding sites as well as facile 
exchange of the whole expression cassettes (Fig. 11A). In addition, the whole 
insert is flanked by AAV ITRs that permit packaging into rAAV particles.  
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Fig. 11: shRNA and TuD can be
expressed from a single vector. A:
Schematic representation of the cloning
strategy for TuD and shRNA cloning. The
vector design allows rapid de novo
cloning of shRNA or TuD binding sites via
BbsI or BsmBI restriction sites,
respectively. shRNA and TuD expression
cassettes can be excised by AscI/NotI
and NheI/SalI digestion, respectively,
permitting easy transfer of whole
cassettes between different vectors. B:
HEK293T cells were transfected with a
single construct carrying shHCV318 and
H1-driven control or specific TuD. Rluc
reporter silencing was measured 48h
post-transfection. RLU=relative light units.
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Along with the two perfect match reporters for antisense and sense strands we 
also included the imperfect target with single mismatch to the sense strand in this 
assay that better represented potential endogenous off-targets. We found that 
with our vector design we could achieve a complete relief of repression of both 
perfect and imperfect sense strand targets in HEK293T cells (Fig. 11B). 
Importantly, the antisense strand remained unaffected. In addition, the ~8-fold 
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attenuation of sense strand activity mediated by the TuD was superior to the 
degree of sense strand counteraction previously observed with the RNA-pol II 
sponges where the effect was less than 4-fold upon transfection into HEK293T 
cells (cf. Fig. 8B). These data suggest that the HCV318 TuD is more potent in 
inactivating the shHCV318 sense strand than the HCV318 sponge. 
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Fig. 12: TuD acts both on protein and mRNA level of target reporters. A: Schematic
representation of the dual f luorescence reporter construct used. d2eGFP allows insertion of
target sites in its 3' UTR and serves as knockdown reporter. mCherry serves as transfection
control. Both proteins are expressed from the same bidirectional CMV promoter (biCMV). B-D:
shHCV318 with control or specific TuD was transfected into HEK293T cells along with dual
f luorescence reporter plasmids carrying the indicated target sites. 48h post-transfection, eGFP
and mCherry were analyzed on the protein level by f luorescence microscopy (B) and FACS
(C) or mRNA levels were visualized by Northern blot (D).
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To confirm these results with another independent reporter system we cloned a 
dual fluorescence reporter plasmid carrying a bidirectional CMV promoter driving 
expression of both destabilized eGFP (d2eGFP) and mCherry (Fig. 12A). 
d2eGFP allows insertion of shRNA binding sites in its 3’ UTR and thus serves as 
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knockdown reporter, whereas mCherry acts as transfection control. Using this 
system, we could confirm the inhibitory effect of the specific TuD on the sense 
strand (Fig. 12B+C). For the unintended perfect target a clear derepression by 
the specific TuD could be observed in fluorescence microscope images while the 
intended target was equally repressed in the presence of either control or specific 
TuD (Fig. 12B). As the inhibitory effect for the imperfect target for the sense 
strand was not well visible in the pictures we also quantified relative eGFP 
expression by dual color FACS analysis (Fig. 12C; see Suppl.Fig. 2 for 
experimental details). The results matched our expectations from the luciferase 
assay. We noted, however, that in the GFP assays repression of the sense 
strand targets was somewhat less pronounced than observed before. This could 
be due to the high eGFP expression levels required for the assay which might 
have led to an unintended sponge effect mediated by the eGFP target transcript. 
We next visualized mCherry and d2eGFP mRNAs by Northern blotting to 
examine the effects of the specific TuD on target transcript levels. As expected, 
we found no change in mRNA levels of the intended target whereas repression of 
the perfect unintended target was relieved (Fig. 12D). The unintended imperfect 
target only exhibited a weak knockdown on the mRNA level which accordingly 
allowed merely a slight relief of repression by the specific TuD. 
For reasons of applicability, we again tested whether this strategy would be 
compatible with rAAV-mediated gene transfer. We therefore packaged 
shHCV318 with either the specific or control TuD and the NSC into self-
complementary rAAV2 vectors and transduced HEK293T cells with. We were 
able to successfully counteract the sense strand showing that the system is 
readily combinable with rAAV technology (Fig. 13A). Although the degree of de-
repression of the unintended perfect target was lower than after HEK293T 
transfection the TuD effect was still ~4.5-fold. We also tested the efficacy of the 
TuD upon transduction of Huh7 hepatocytes which is a far more relevant setting 
in case of our anti-HCV shRNA which is supposed carry out its function in the 
liver. In this cell type, the overall knockdown of the three tested targets was more 
pronounced than in HEK293T cells (Fig. 13B). Nevertheless, we achieved a ~6-
fold or ~3.5-fold de-repression of the unintended perfect or imperfect target, 
respectively, without affecting the antisense strand. 
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Fig. 13: Translation of the plasmid-based transfection system into rAAVs. A-B: Sense
and antisense strand activity of H1-shHCV318 were measured by dual luciferase assay 48h
af ter transduction of HEK293T (A, MOI=5x104) or Huh7 (B, MOI=105) cells with rAAV2 vectors
carrying shRNA and TuD as indicated. C: Huh7 cells were transduced (MOI=105) with rAAV2
encoding shHCV318 with control or specific TuD. 48h post-infection total RNA was purif ied,
and shRNA and TuD were visualized by small RNA Northern blot. D: Huh7 cells were
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We next tested whether TuD co-expression had any influence on the intracellular 
levels of the shHCV318 sense strand. In agreement with previously reported data 
we did not see any alterations in sense strand expression by small RNA Northern 
blotting, suggesting a mode of action that is solely based on competitive 
sequestration (Haraguchi et al., 2009; Fig. 13C). In the shown blot the TuD was 
detected with the same probe as the antisense strand. Since this probe had a 
single mismatch towards the TuD binding site the signal intensities do not 
represent the relative levels of TuD and shRNA expression. To better estimate 
the relative expression levels of the two molecules we therefore also detected the 
TuD with a perfect match probe. Our results showed that TuD levels by far 
exceed shRNA levels (Suppl.Fig. 3).  
We furthermore examined the concentration dependency of our strategy by 
infecting Huh7 cells at different MOIs. This titration experiment showed that the 
specific TuD is efficacious over a wide range of vector dose (Fig. 13D). Maximal 
effects were observed when sense strand activity was strong in the first place, i.e. 
at MOI 104 and 105 (Fig. 13E).  
3.3.2 TuD co-expression does not interfere with intended target silencing 
We next wanted to prove the utility of the approach by moving away from reporter 
assays towards real shRNA targets. Firstly, we thus had to show unaltered 
silencing efficiencies mediated by the antisense strand on the intended target -i.e. 
HCV virus RNA- with the specific TuD as compared to the control. Secondly, we 
needed to prove that under similar conditions sense strand-mediated silencing of 
endogenous off-target genes is indeed diminished by the specific TuD.  
We therefore conducted the same HCV inhibition experiments as previously with 
the shRNA-sponge constructs. In agreement with the results obtained in the 
reporter assays we did not observe any differences in HCV silencing by 
shHCV318 with specific or control TuD (Fig. 14A+B). The degree of HCV 
inhibition was similar to what we had observed with the shHCV318-sponge 
vectors at MOI 105 (cf. Fig. 9A+B).  Notably, at lower MOIs the shHCV318-TuD 
vectors outperformed the shHCV318-sponge vectors. 
69 
 
RESULTS 
______________________________________________________________________________ 
 
 
Fig. 14: shHCV318 on-target silencing. A+B: Inhibition of HCV replication by shHCV318
af ter transduction of Huh7 cells carrying subgenomic replicons of HCV genotype 1b (A) or 2a
(B) at indicated MOIs 48h post-infection. HCV replication was quantif ied by measurement of
Fluc activity encoded by the HCV replicons. MOI=multiplicity of infection.
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3.3.3 TuD co-expression de-represses endogenous sense strand off-targets 
and reduces overall perturbance of gene expression 
We considered it reasonable to use the highest vector dose for subsequent 
analysis of erroneous silencing of untargeted endogenous genes as in this 
particular application of HCV inhibition it is necessary to achieve maximal levels 
of RNAi potency. We therefore transduced Huh7 cells under similar conditions as 
previously the Huh7 replicon cells, extracted total RNA 48h post-transduction and 
analyzed the expression profiles by microarray covering the whole human 
transcriptome (Illumina HumanHT-12, conducted by DKFZ core facility).  
After filtering out transcripts with too little difference to the background we found 
1002 genes of a total of 17367 genes on the chip to be significantly different in at 
least one sample as compared to the NSC (T-test, unpaired, two-sided, p<0.01). 
Of these, 596 only differed mildly (less than 2log(0.5)-fold difference) from the 
NSC and were thus not further analyzed (Fig. 15, grey square). 166 genes were 
considered down-regulated (relative expression < 2log(-0.5)) upon expression of 
shHCV318 with the control TuD. Importantly, 111 of these were less down-
regulated in the presence of the specific TuD with 38 reaching statistical 
significance (Fig. 15, left green square; T-test, unpaired, two-sided, p<0.01). In 
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contrast, of the 86 genes down-regulated upon co-expression of the specific TuD 
only 31 were concomitantly less down-regulated with the control TuD with only 3 
being significantly different (Fig. 15, lower red square).  
 
Fig. 15: Sense strand TuD reduces global perturbation of gene expression. Huh7
expression profiles after transduction with rAAV2 carrying either shHCV318 with control or
specif ic TuD or a NSC (MOI=105). Dysregulated genes in one or both samples (T-test,
unpaired, two-sided, p<0.01) were plotted. Numbers indicate gene counts in each area. Counts
for genes that are statistically signif icantly different (T-test, unpaired, two-sided, p<0.01) in both
samples are given in brackets. MOI=multiplicity of infection; NSC=non-silencing control.
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Likewise, for the up-regulated genes (relative expression > 2log(0.5)) we 
observed a similar attenuating effect by the specific TuD. Of 168 genes that were 
up-regulated in the cells treated with shRNA and control TuD 109 were closer to 
the NSC in the cells treated with shRNA and specific TuD (19 significant, Fig. 15 
right green square) while the other way around only 41 out of 100 were less up-
regulated (4 significant, Fig. 15 upper red square).  
These results show that the perturbation of the transcriptome produced by 
expression of shHCV318 is partly alleviated when the specific sense strand TuD 
is co-expressed. Generally, it is noteworthy that the overall levels of dysregulation 
after transduction with our shRNA-TuD-encoding rAAV2 vectors were modest 
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with the strongest response being less than 3-fold which is in the same range as 
previously reported shRNA off-target effects (Jackson et al., 2006a). 
To prove that the observed attenuating effect by the specific TuD was indeed due 
to the inhibitory effects of the specific TuD on the shRNA sense strand, we 
analyzed the 3’ UTRs of two different gene groups for the enrichment of specific 
sequences. The first gene group that was analyzed showed down-regulation by 
shHCV318 in the presence of the control TuD but not the specific TuD (Fig.  15, 
Group 1, only statistically significant genes were analyzed). If our system was 
working, this group should represent the endogenous off-targets of the shRNA 
sense strand that were rescued by the specific TuD. We therefore expected an 
enrichment of sense strand seed matches in the 3’ UTRs of genes in Group 1. 
The second group of interest was down-regulated by shHCV318 regardless of 
whether we co-expressed control or specific TuD (Fig.  15, Group 2) and should 
contain targets of the antisense strand. Genes in Group 2 should thus be 
enriched in antisense strand seed matches in their 3’ UTRs.  
Frequencies of the indicated sequences in both groups were compared to the 
background frequencies in all transcripts analyzed on the microarray chip. 
Positions and sequence of the seed regions of both sense and antisense strand 
are given in Fig. 16A. We indeed observed a significant enrichment of sense 
strand seed matches in the 3’ UTRs of Group 1 genes with a concomitant non-
significant decrease in Group 2 (Fig. 16B). Although non-significant this latter 
effect may indicate that genes that were silenced by shHCV318 and carried a 
sense strand seed were more likely to fall into Group 1 so that there was a 
depletion of this motif in Group 2. The most significant and strongest enrichment 
of complementary seed sequences in Group 1 was found for a full match from 
nucleotide 1-8 where it was almost 5-fold (Fig. 16B).  
When analyzing antisense strand seed matches we saw a significant enrichment 
in Group 2 but not in Group 1 (Fig. 16C). Again, the strongest enrichment was for 
the full octamer seed match (over 9-fold for nt 3-10). We also observed an 
apparent enrichment of antisense strand nt 3-9 matches in Group 1, yet the level 
of significance was very low (p=0.04) and neither of the other sequences was 
significantly enriched. As a whole, our results suggest that the specific TuD 
indeed counteracted endogenous off-target effects mediated by the sense strand 
and thereby alleviated dysregulation of gene expression. 
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Fig. 16: Sense strand TuD relieves silencing of endogenous sense strand off-targets. 3'
UTR sequences of genes in either Group 1 or 2 as def ined in Fig.15 were extracted from the
Refseq database and analyzed for the presence of either sense or antisense strand seed
matches. A: Structure of shHCV318 with potential Dicer processing product (indicated by blue
dotted lines) and respective octamer seed regions for the sense and antisense strand. B-C:
Enrichment of sense strand seed matches (B) or antisense strand seed matches (C) in 3'
UTRs of indicated gene groups. For Group 1 only statistically signif icant hits were analyzed.
Chip=all genes on the miArray chip (=background set); n=number of genes with extractable
sequences.
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Expression profiling was conducted with only one NSC that carried the specific 
TuD. We hence wanted to rule out the possibility of unspecific effects by the 
specific TuD which would not be visible in the miArray data. We therefore 
extracted total RNA from Huh7 cells that had been treated as before and also 
included two more controls, i.e. a second NSC that carried the control TuD as 
well as naïve Huh7 cells. We then analyzed the most significant hits from Group 
1 (SEPT9) and Group 2 (CIRBP) as well as an unregulated gene (RAN) by 
reverse transcription quantitative PCR (RT-qPCR). We found that although the 
degree of silencing of CIRBP was less pronounced and knockdown of SEPT9 
was stronger all three genes behaved as in the miArray (Suppl.Fig. 4). 
Importantly, the two NSC controls did not differ for those two genes and only for 
RAN we observed a slight upregulation in the NSC with control TuD. SEPT9 was 
slightly lower expressed in naïve Huh7 cells than in the two NSCs with the NSC 
with specific TuD reaching statistical significance. In general we did not detect 
any aberrant behavior of the NSC with specific TuD. 
In addition to RT-qPCR analysis, three 3’ UTRs of genes from Group 1 (CLCN7, 
BCL7B and FRMD8) that contained sense seed matches and one 3’ UTR of a 
gene from group 2 (CIRBP) that contained an antisense seed match were cloned 
into the 3’ UTR of a Rluc reporter. SEPT9 was not used as it does not contain 
any sense strand seed match in its 3’ UTR. It is thus likely an indirect target of 
shHCV318 so that 3’ UTR cloning would not necessarily reflect the situation of 
the endogenous transcript. Huh7 cells were subsequently transduced with the 
same vectors and MOI as before and additionally transfected with the 
endogenous off-target reporters. The obtained luciferase data further confirmed 
the validity of the miArray results (Fig. 17A+B). Both CLCN7 and BCL7B 3’ UTR 
reporters were highly significantly silenced by shHCV318 and this effect could be 
partially counteracted by the specific sense strand TuD which is in accordance 
with the data obtained from the miArray. For the FRMD8 3’ UTR reporter, 
however, we only observed a weak knockdown effect. We did not see any 
ameliorating effect of the specific TuD, either. For technical reasons only a 
stretch of 1.4kb of the FRMD8 3’ UTR containing the sense seed match was 
cloned. A possible reason for the discrepancy between the degree of silencing of 
the FRMD8 3’ UTR reporter and the degree expected from our miArray data may 
therefore be that recognition of the sense binding site is influenced by 
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downstream sequences that were not cloned or also by upstream regions within 
the FRMD8 CDS. 
 
 
B
A
Fig. 17: Validation of shHCV318 off-targets by 3' UTR cloning. A: 3' UTRs of three Group
1 genes (CLCN7, BCL7B, FRMD8) carrying sense strand seed matches and of one Group 2
gene (CIRBP) carrying an antisense seed match were cloned into the 3' UTR of a Rluc
reporter. Huh7 cells were transduced with rAAV2 vectors carrying shRNA and TuD as
indicated (MOI=105) and co-transfected with the off -target reporters or a perfect antisense
reporter (Intended) as control. 48h post-transfection reporter silencing was measured by dual
luciferase assay. Signif icance was determined by an unpaired, two-sided T-test (* p<0.05; **
p<0.005; *** p<0.0005). B: miArray results for the same genes for comparison.
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The Group 2 reporter carrying the CIRBP 3’ UTR was silenced in the presence of 
both control and specific TuD as expected. Likewise, silencing of the perfect 
match target for the antisense strand that was measured in parallel as control 
was not affected. Importantly, we did not observe any different behavior between 
the two NSC for any of the 3’ UTR reporters. Taken together, the RT-qPCR and 
3’ UTR results therefore at least partly confirmed the validity of the results from 
expression profiling. 
 
3.4 Effect of shRNA and TuD expression on the endogenous 
miRNA pathway 
Previous studies have shown the perturbation of the endogenous miRNA 
pathway upon shRNA expression both in vivo and in vitro (Grimm et al., 2006a; 
Pan et al., 2011). This could be linked to oversaturation of protein factors such as 
Exportin-5. As TuD molecules are also hairpin structures that are exported from 
the nucleus by Exportin-5, TuD expression might likewise interfere with miRNA 
functionality. We therefore examined potential adverse effects of our expression 
system on the miRNA pathway. To this end, we compared miR-122-5p 
expression levels in Huh7 cells transduced with shHCV318 and either control or 
specific TuD to naïve Huh7 cells. We found that miR-122-5p expression was 
mildly reduced in the cells expressing shHCV318 (Fig. 18A). The two NSC with 
either control or specific TuD did not produce any noticeable alterations in miR-
122-5p expression indicating that TuD co-expression does not derogate miRNA 
maturation like shRNAs. We next examined whether the mild miR-122-5p 
reduction in the two shHCV318 samples had any functional consequences on 
target silencing. We went back to our miArray data and analyzed relative 
expression levels of a set of 25 experimentally validated miR-122-5p targets 
(TarBase 6; Vergoulis et al., 2012). In case of reduced miR-122-5p activity in our 
samples we would expect a general up-regulation of its targets in our dataset. 
However, in agreement with the only weakly altered intracellular miR-122-5p 
levels, no such up-regulatory effect was observed for shHCV318 with control or 
specific TuD (Fig. 18B). In the same manner we also analyzed target genes of 
other miRNAs expressed in Huh7 cells according to the microRNA.org database. 
We observed a slight tendency towards up-regulation of target genes of the 
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analyzed miRNAs (Suppl.Fig. 5). Yet, the degree of this dysregulation was minor. 
We hence conclude that despite the observed reduction in miR-122-5p levels 
shHCV318 expression did not generally perturb the miRNA pathway and no signs 
of adverse effects of TuD expression were detected in our experimental system.  
 
A
Fig. 18: Effects of shHCV318 expression on miRNA pathway. A: miR-122 expression in
naive Huh7 cells or 48h af ter infection with rAAV2 carrying shRNA and/or TuD as indicated
(MOI=105). B: 25 targets (TarBase 6) of miR-122 were analyzed for dysregulation in the
miArray data generated before. The mean relative expression in both data sets does not differ
considerably f rom the NSC and differences between the two set were not signif icant (T-test,
unpaired, two-sided, p<0.05).
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3.5 Adaptation of TuD strategy to different shRNAs  
To adapt the sense strand inhibition strategy to additional unrelated shRNAs we 
first used hAAT25 as its strand activities had been characterized already. Two 
target sites with single mismatches that we had found in the random target 
screen were used for construction of an H1-TuD against the hAAT25 sense 
strand. By utilizing the same vector backbone as previously for shHCV318 we 
achieved an over 3-fold improvement of the relative strand activities for hAAT25 
after plasmid transfection in HEK293T cells (Suppl. Fig. 6A). We next packaged 
the vector into rAAV2 and tested strand activities upon Huh7 transduction. In this 
setting no significant sense strand counteraction by the TuD could be observed 
(Suppl. Fig. 6B). We argued that this issue could be solved by increasing TuD 
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expression levels relative to shRNA levels and tested this hypothesis by 
exchanging the H1-TuD by a U6-TuD of the same sequence. Indeed, we were 
able to successfully counteract the sense strand both after transfection and 
transduction (Fig. 19A-B). Vector titration experiments showed that the U6-TuD 
reduced hAAT sense strand activity at high MOIs with maximal effects of over 
2.5-fold (Fig. 19B).  
We next also constructed a U6-driven TuD against the sense strand of another 
shRNA that is directed against the hepatitis B virus sAg termed shHBVS122nt. 
This shRNA was based on a previously published 20-mer shRNA that had been 
successfully used for HBV inhibition in mice (Chen et al., 2006). As with 
shHCV318 previously we added 2nt to the shRNA to obtain a stem of 22nt so 
that the shRNA would fit to the design rules. We constructed a U6-TuD 
containing two target sites with single mismatches similar to what we had used 
before. As with hAAT25, we saw an over 3-fold inhibitory effect after transfection 
of HEK293T cells (Fig. 19C). Upon rAAV2-mediated delivery of shHBVS122 to 
Huh7 cells, co-expression of the specific TuD achieved a modest but significant 
sense strand counteraction of 1.5-fold at the highest MOI (Fig. 19D). 
To more easily compare the results for the different shRNAs, we calculated and 
plotted the RSAs for all three shRNAs tested at the different MOIs after Huh7 
transduction (Fig. 19E). In the presence of the control TuD, the three shRNAs 
displayed remarkably different behaviors in terms of strand activities. The strands 
of shHCV318 have more or less the same activities and the RSA does not 
change with increasing MOIs. hAAT25 naturally has a good RSA which drops at 
the highest MOI. shHBVS122 has an intermediate RSA at he lowest MOI which 
drops already at MOI 104 and remains constantly low at MOI 105. The shRNAs 
also differ in their responsiveness to the TuD with shHCV318 allowing the highest 
degree of counteraction, and with hAAT25 reaching the best RSA values in 
combination with its specific TuD. All three shRNAs have in common that 
improvement of RSA via the specific TuD increases with MOI further strongly 
supporting the model emerging from this work that TuD activity is dose-
dependent (see section 4.1). 
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3.6 Optimization of TuD-mediated sense strand inhibition 
3.6.1 Single perfect match target sites are sufficient for optimal TuD activity  
In parallel to proving the functionality and utility of the approach we also 
determined a set of design parameters for both TuDs and shRNAs. Although our 
previous TuDs all had imperfect targets our strategy would greatly benefit from 
the possibility of using perfect binding sites as this would allow easier target site 
design and selection. 
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Fig. 20: TuD binding site analysis. A:
HEK293T cells were transfected with
hAAT25 and TuDs with different binding
site conf igurations in trans and a luciferase
reporter for the hAAT25 sense strand.
Luciferase knockdown was measured 48h
post-transfection. Signif icance was
determined by unpaired, two-sided T-test
(*** p<0.0001). B: Schematic
representation of a chimeric TuD molecule
containing one perfect binding site (bs)
each for the sense strands of hAAT25 and
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In the original description of TuDs as inhibitors of miRNA activity, the authors 
suggested imperfect binding sites for TuD construction to achieve maximal 
effects with miR-21-5p as an example (Haraguchi et al., 2009). Yet, in a follow-up 
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study with synthetic TuD-based inhibitors they obtained best results with a perfect 
match target for two other miRNAs (Haraguchi et al., 2012). They also linked the 
unsatisfactory performance of the miR-21-5p TuD with the perfect target to 
extensive base pairing between the two TuD target sites which could inhibit 
miRNA binding. It therefore appears that miR-21-5p is a special case and we 
consequently tested whether perfect target sites would also work in our 
approach. In addition, we also examined the importance of the number of target 
sites within the TuD as it would facilitate the construction of the expression 
cassette being able to reduce it to only one single binding site.  
We hence generated TuDs that had different configurations of perfect or 
imperfect and one or two binding sites for the hAAT25 sense strand, and then 
transfected shRNA and TuD in HEK293T cells at equal amounts from separate 
plasmids. We found that under the conditions tested bulged and perfect target 
sites in the TuD worked equally well and it also did not make any significant 
difference whether the TuD contained one or two binding sites for the shRNA 
sense strand (Fig. 20A). None of the TuDs rescued expression of the sense 
strand target to 100%, allowing us to conclude that there was no apparent 
oversaturation which might obscure subtle differences in performance between 
the configurations. Our findings led us to test the possibility of generating a 
chimeric TuD that would counteract the sense strands of two shRNAs at the 
same time. To this end, we constructed a TuD with one perfect binding site for 
the hAAT25 sense strand and another perfect binding site for the shHCV318 
sense strand (Fig. 20B). We transfected HEK293T cells with shHCV318 or 
hAAT25 and the chimeric TuD and measured luciferase knockdown of sense 
strand targets for both shRNAs 48h post-transfection. Indeed, our design allowed 
us to counteract both sense strands with one single construct (Fig. 20C). 
3.6.2 5’ but not 3’ strands can be counteracted by TuDs or sponges 
We had shown before that 5’ and 3’ strands rely on different principles of 
maturation (cf. Fig. 5). In an effort to further characterize our system of TuD-
mediated sense strand counteraction, we also tested whether it made a 
difference if the sense strand was located at the 5’ or 3’ end of the shRNA 
molecule. To this end, we cloned an additional TuD directed against the hAAT 
antisense strand that in the case of hAAT25 is located at the 3’ end of the 
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shRNA. We then examined hAAT sense and antisense TuD activities on hAAT25 
as well as an additional shRNA with inverted strand order named hAAT25R (Fig. 
21A; Grimm et al., 2006a). It has to be noted that even though the sequences of 
both shRNAs are in principle the same, Dicer processing likely generates sense 
and antisense strands that are not completely identical. TuDs with mismatch 
targets that are designed for the hAAT25 sense strand are therefore probably not 
suitable for hAAT25R. To avoid erroneous results, we hence used perfect match 
TuDs that should be active regardless of the exact nature of the mature strands 
(Fig. 21A). We transfected HEK293T cells with shRNA and TuD at equal 
amounts as well as with perfect Rluc reporters for either shRNA strand. We found 
that only the 5’ strand of hAAT25 and hAAT25R could be counteracted (Fig. 
21B).  
We knew that for hAAT25 the antisense strand was expressed at much higher 
levels than the sense strand so that the reason for the observed effect could lie in 
too high expression of the strand (cf. Fig. 4D). Alternatively, the susceptibilities to 
counteraction might be inherent features of the respective strands. We argued 
that in case of a dosage effect limiting the shRNA amounts should enable the 
TuD to counteract the 3’ strands. To address this question, we repeated the 
same assay as before but this time with a constant high amount of TuD and 
decreasing amounts of shRNA. hAAT19 was also included in this experiment (cf. 
Fig. 21A). This shRNA has the same configuration and sequence as hAAT25 but 
its antisense strand levels are much lower. In case of a dosage effect the 3’ 
antisense strand should therefore be easier to counteract for hAAT19 than for 
hAAT25. As expected, we found that the 5’ sense strand of all three shRNAs 
could be efficiently counteracted (Fig. 22A). Yet, we were unable to counteract 
the 3’ strand of any of the three shRNAs even at the lowest shRNA dose (Fig. 
22A). The antisense TuD worked with hAAT25R, indicating that this TuD was 
functional even though it had no effect on the hAAT19 and -25 antisense strands. 
This was observed even though we were not working under saturated conditions 
anymore so that the 3’ strand levels were limited, suggesting that our inability to 
counteract the 3’ strand was not due to too high expression levels of this strand. 
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Fig. 21: Efficacy of TuD strategy depends on shRNA strand order. A: Schematic
representation of the different shRNA conf igurations and TuDs used. B: HEK293T cells were
transfected with equal amounts of shRNA and TuD as well as with luciferase reporters for both
strands as indicated. Activity of either strand was measured by dual luciferase assay 48h post-
transfection.
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To investigate whether this effect was specific to TuD-mediated inhibition, we 
conducted an analogous experiment with RNA-pol II sponges. To this end, we 
co-transfected shHCV318 with the dual fluorescence reporter system described 
earlier (cf.Fig. 12). We transfected a constant amount of the shRNA and 
increasing amounts of perfect target reporters for the 5’ or the 3’ strand. From a 
certain concentration, we expected the d2eGFP targets to act as sponges which 
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would lead to decreased potencies of silencing and hence increased eGFP 
expression levels. Indeed, we saw that the degree of silencing of the 5’ strand 
target decreased at high reporter levels (Fig. 22B). However, we did not see such 
an effect for the 3’ strand where the degree of silencing remained constantly high 
over the whole range of tested concentrations.  
The fact that both TuD and sponge were unable to counteract shRNA 3’ strands 
thus implies that there is an as of yet unknown functional difference between the 
two strands of shRNAs with perfect stems. 
 
3.7 Alternative uses of our bi-functional vectors 
In certain applications it could be useful to combine RNAi with miRNA inhibition. 
For this purpose our vector design is ideal as it permits co-expression of an 
shRNA and an inhibitor RNA from one single rAAV vector. One such application 
could again be HCV inhibition. The liver-specific miR-122-5p plays a fundamental 
role for the virus and reduction of miR-122-5p activity drastically decreases HCV 
replication (see section 1.2). A powerful approach for HCV inhibition might hence 
be to combine RNAi and miR-122-5p inhibition. To test the general feasibility of 
this concept, we generated a TuD directed against miR-122-5p using a vector 
construct derived from this study. 
We first tested functionality of the TuD by transfecting HEK293T cells with an 
shRNA mimicking miR-122 along with control or specific TuD and an imperfect 
target reporter for miR-122-5p. The TuD efficiently counteracted miR-122-5p 
target inhibition thereby proving its functionality (Fig. 23A). We next packaged 
control and specific TuD into rAAV2 vectors and transduced Huh7 cells carrying 
HCV replicons of genotype 1b. We observed a dose-dependent inhibition of HCV 
replication of up to 20-fold. These promising results demonstrate that our vectors 
are easily adaptable for rAAV-mediated miRNA inhibition. We are currently 
testing the possibility of combining shRNA and miRNA TuD in a single vector.  
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Fig. 23: HCV inhibition by TuD-mediated miR-122-5p inactivation. A: HEK293T cells were
transfected with sh122SA (an shRNA mimicking miR-122), a miR-122-5p target reporter and a
control or specif ic TuD against miR-122-5p. Reporter knockdown was measured 48h post-
transfection by dual luciferase assay. Statistical analysis: unpaired, two-sided T-test, **
p<0.005. B: Inhibition of HCV replication by the miR-122-5p TuD after transduction of Huh7
cells carrying subgenomic replicons of HCV genotype 1b at indicated MOIs 48h post-infection.
HCV replication was quantif ied by measurement of Fluc activity encoded by the HCV
replicons. MOI=multiplicity of infection.
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4 DISCUSSION 
In this study, we set up a novel system to improve relative shRNA strand 
activities in order to increase specificity without compromising the silencing 
potential of the antisense strand. Our method is based on sequestration and 
concomitant partial inactivation of shRNA sense strands by inhibitor RNA 
molecules carrying specific binding sites. In our experiments, we observed strong 
sense strand activities for all shRNAs tested despite of naturally occurring strand 
biasing mechanisms that favor activation of the antisense strand. Importantly, we 
could prove that the sense strand of an exemplary anti-HCV shRNA indeed 
contributed to off-target silencing of endogenous genes and that this could be 
counteracted by our inhibition method. The results on functional characterization 
of shRNAs and inhibitor molecules as well as potential future applications and 
improvements of our method will be discussed in the following.  
 
4.1 Sense strand activity and its counteraction 
4.1.1 Alleviation of off-targeting by sense strand inhibition 
In this study, we provide detailed data about the relative strand activities of 
shRNAs with perfectly matched stems. We could show that these RNAi triggers 
have a general functional bias towards the 3’ strand when the stem of the shRNA 
accounts for more than 21 nucleotides. The undesired sense strand should 
therefore be placed at the 5’ end of the molecule to reduce its activity. Yet, we 
found that despite this design rule the sense strands of all tested shRNAs were 
highly active, albeit to varying degrees. This is in contrast to previous studies that 
showed an almost complete lack of sense strand activity (Boudreau et al., 2008; 
Boudreau et al., 2011; Gu et al., 2011). The general design of the shRNAs used 
in these studies (RNA-pol III-expressed, stem longer than 20nt, sense strand at 5’ 
end, 3’ overhangs of 2nt) is similar to ours so that this factor alone cannot explain 
the discrepancy to our results. The only noticeable difference lies in the loop 
sequence. However, in the aforementioned studies the applied loops were copied 
from two endogenous miRNAs -miR-30 and miR-22, respectively- whose natural 
strand bias according to miRBase 18 is towards the 5‘ strand (see section 6.2 for 
weblink to database). It therefore seems highly unlikely that these particular 
sequences increase the activity of the 3’ strand in the context of an artificial 
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shRNA molecule. The variability in strand biasing observed with our own shRNAs 
rather suggests that strand selection mechanisms are strongly influenced by the 
nature of the stem sequence which in turn depends on the shRNA target site. It is 
hence possible that the high degree of strand biasing observed in the 
aforementioned studies was simply due to the nature of their target sequences. 
However, in some applications this parameter cannot be freely chosen, e.g. in the 
case of certain viruses the choice of target sites is rather limited.  
These considerations imply that the sense strand cannot be readily inactivated 
for any given shRNA by placing it at the 5’ end of the molecule. This is 
exemplified by our anti-HCV shRNA that exerted high levels of sense strand 
activity which also contributed to off-target silencing of endogenous genes under 
the tested experimental conditions. For this shRNA the options for reduction of 
sense strand activity are limited. Although our data suggest that this is possible 
by lowering the intracellular shRNA amounts it is at the cost of also losing the 
optimal potency of the antisense strand which in the case of shHCV318 would be 
counterproductive. In addition, fine-tuning of the intracellular shRNA levels is not 
readily achievable in all settings which is true especially in in vivo experiments. 
Upon systemic administration it is difficult to deliver an exact vector dose, e.g. to 
the liver, to precisely tune shRNA expression. 
Expression profiling by miArray revealed that global dysregulation of gene 
expression in transduced Huh7 cells induced by shHCV318 could be reduced by 
co-expression of a TuD molecule for the shRNA sense strand. This effect could 
be linked to specific de-repression of off-targets carrying sense strand seed 
matches. From this we conclude that sense strand sequestration may indeed 
increase shRNA specificity. We suggest that our method may be especially 
useful in the case of shRNAs whose strand bias is not well pronounced due to 
the nature of their target sequence. 
4.1.2 Considerations on inhibitor functionality and mode of action 
Using RNA-pol III-transcribed TuD molecules we were able to reduce the sense 
strand activities of three independent shRNAs. An interesting and initially 
unexpected observation was that the degree of sense strand counteraction 
differed considerably between these shRNAs. Best results were obtained with 
shHCV318 followed by hAAT25 and then shHBVS122. All three shRNA have 
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their sense strand activities in the same range (90-95% silencing upon Huh7 
transduction) and yet differ in their responsiveness to the TuD. In a recent study it 
has been suggested that the extent of base pairing between the two TuD binding 
sites is indicative of TuD functionality (Haraguchi et al., 2012). In case of 
extensive interaction between the two strands (over nine base pairs as predicted 
by Centroid fold, see section 6.2 for weblink) the TuD could lose its activity 
because the binding sites are not accessible. However, for all of our TuDs we 
only found very little predicted interaction between the two binding sites so that 
this issue apparently does not play a role here. We therefore propose another 
theory in which the different efficiencies of our TuDs are linked to the sequence of 
the shRNA. The thermodynamic stability of the seed-target duplex has been 
shown to be a determinant of how well a target can be bound (Naito et al., 2009). 
Due to the nature of its target site shHCV318 has a much higher GC content in its 
sense strand seed (75%) as compared to hAAT25 or shHBVS122 (50% and 
37.5%, respectively) which is a good indicator for the thermodynamic stability of 
the seed-target duplex. Curiously, the GC contents correlate with the efficiencies 
of the TuDs. We therefore argue that the inhibitory effect might be more 
pronounced with shHCV318 than with the other two shRNAs because the binding 
affinity to the TuD is strongest. 
Another essential factor that severely influenced the efficacy of our approach 
appeared to be the relative expression of shRNA and inhibitor RNA. This is 
supported by the fact that for hAAT25 we could improve the strategy by replacing 
the H1 by the stronger U6 promoter. Our rAAV titration experiments in Huh7 cells 
further demonstrated that the degree of sense strand counteraction by the TuD 
was dependent on the vector dose. The higher the dose the better the effect (for 
shHCV318 a plateau was reached already at MOI 104). We conclude that the two 
molecules have different expression kinetics, with shRNAs reaching activities 
close to the maximum at lower vector doses than the inhibitor molecule. This is 
not necessarily a drawback of the strategy as sense strand counteraction is 
especially important at higher MOIs where silencing is most pronounced. TuDs 
may hence buffer sense strand activity at doses where it is especially needed.  
Our system behaved differently in transfection and transduction experiments. 
This becomes evident when looking at sense strand counteraction for shHCV318 
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which was over 8-fold upon HEK293T transfection but only ~4.5-fold upon 
transduction of the same cells even though sense strand activity per se was 
similar in both settings (cf.Fig. 10B and 12A). A comparison between HEK293T 
transfection and Huh7 transduction for all shRNAs hints into the same direction 
for all shRNAs. We hence conclude the gene delivery method has a critical 
influence on the efficiency of our strategy.  
It has been shown previously that RNA targets induce miRNA degradation by 
certain tailing and trimming mechanisms (Ameres et al., 2010). A recent 
publication on the use of TuDs for miRNA counteraction in mice and cultured 
human cells showed similar effects (Xie et al., 2012). These authors hence 
claimed that TuD activity is based on target miRNA degradation. However, 
neither we nor the original study on TuDs found any changes in shRNA or miRNA 
levels upon TuD expression, respectively (Haraguchi et al., 2008). In the results 
of Xie and colleagues the reduction in target miRNA levels is potent (>4-fold) 
when measured by RT-qPCR but subtle (~1.5-fold) when visualized by Northern 
blot. The same discrepancy was observed by Haraguchi and colleagues before 
and they hypothesized that TuD-miRNA interaction might interfere with proper 
detection by RT-qPCR. Therefore Northern blotting under denaturing conditions -
as done in our study- appears to be better suited to gain insights into the 
intracellular levels of the miRNA or shRNA strand that is to be inhibited. Important 
to point out again, the present work is the first to employ TuD technology in the 
context of shRNAs. Therefore, our data not only validate the mechanism of TuD 
inhibition via target RNA sequestration, but concurrently also extend this finding 
to an entirely different class of small RNAs. 
4.1.3 Parameters for optimal TuD design 
Expression of inhibitor molecules like TuDs can lead to sequestration of specific 
miRNAs due to sequence homologies. It has recently been shown that a seed 
match alone is not sufficient for miRNA counteraction by TuD-like inhibitors 
(Haraguchi et al., 2012). Extensive base-pairing at the 3’ end of the miRNA was 
required in addition to the seed match indicating that the target requirements for 
efficient counteraction are rather stringent. Nevertheless, it is important to 
exclude sequences with high homologies to cellular miRNAs when designing TuD 
target sites and to omit seed matches as effectively as possible. 
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Our data demonstrates that binding sites with perfect complementarity to the 
shRNA sense strand work as equally well as mismatched targets. This finding 
indicates that the design rules in the original report might not be optimal for all 
RNAi triggers (Haraguchi et al., 2008). The initial notion that perfect binding sites 
worked less efficiently than mismatched counterparts was only based on one 
single miRNA, i.e. miR-21-5p. In a recent follow-up study the same authors 
tested counteraction of several miRNAs -including miR-21-5p- with synthetic 
TuD-like inhibitors (Haraguchi et al., 2012). They showed that miR-21-5p is a 
special case as for two additional miRNAs they found best counteraction via 
perfect match targets strongly supporting our data on target site requirements. 
The authors linked poor performance of the miR-21-5p TuD with perfect target to 
extensive base pairing between the two target sites which could limit accessibility 
for the miRNA. In combination with our own results we therefore assume that 
binding site requirements for miRNA and shRNA inhibition are similar and that 
perfect binding sites for TuD construction are generally at least as potent as 
mismatched counterparts. The latest results of Haraguchi et al. even support the 
idea that perfect sites could in general be better than imperfect sites since TuD 
efficiency appears to increase with homology to the target. The fact that perfect 
and mismatched targets performed equally well in our assays does not contradict 
this hypothesis. All our imperfect targets had single central mismatches which 
probably only marginally reduced the stability of the resulting TuD-sense duplex 
as compared to perfect match targets.  
While the possibility to use perfect target sites for TuD construction is important in 
terms of design rules, it is also interesting from a biological perspective. In the 
original report on miRNA sponges the authors showed that for both RNA-pol II- 
and RNA-pol III-transcribed inhibitors perfect target sites were outperformed by 
imperfect counterparts (Ebert et al., 2007). The most likely explanation for this is 
efficient degradation via hAgo2-mediated slicing and hence reduced activity of 
perfect match inhibitors as compared to mismatched ones. As this effect -i.e. 
superior performance of imperfect versus perfect targets- is absent in TuDs we 
suggest that perfect binding sites in TuDs are apparently not readily sliced by 
hAgo2. This might be because the complex structure of the TuD does not allow 
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proper positioning of the target site relative to the RNAi trigger so that no slicing 
reaction can occur.   
A particularly novel and important finding during our comprehensive analysis of 
various TuD designs was that single target binding sites already suffice to yield 
maximum inhibition. The fact that we did not see any disparity between TuDs with 
one or two binding sites suggests that the intracellular TuD concentration is more 
important than the number of targets. In any case, it is questionable whether it 
would be sterically possible for one single TuD molecule to bind two sense strand 
loaded RISCs at the same time. Our finding opens up the possibility to generate 
inhibitors that inhibit two RNAi triggers at the same time as exemplified by our 
chimeric TuD against hAAT25 and shHCV318. We are convinced that this 
concept will prove useful in applications where multiple shRNA sense strands 
and/or miRNAs should be counteracted (see section 4.3.4).  
Taken together, our data identified two essential design parameters that 
determine the efficiency of this inhibitor class: 1) Perfect binding sites work better 
than imperfect sites, 2) a single perfect binding site suffices to yield maximum 
inhibition. For future de novo construction of TuDs both against shRNA sense 
strands and miRNAs we therefore recommend to use single perfect binding sites 
if possible. This allows easy design and cost- and time-effective cloning 
procedures. If a perfect target happens to insufficiently inhibit sense strand or 
miRNA activity -as in the case of miR-21-5p- or if the sequence of the binding site 
exhibits homologies to untargeted miRNAs, high affinity targets with single 
mismatches at position 10 or 11 can be used instead. 
4.1.4 Possible optimizations 
Although we were able to achieve an improvement of relative strand activity for 
all three shRNAs we clearly see room for further optimization of the strategy. 
Based on our results with our first generation of TuD vectors, we envision the 
following beneficial modifications in future designs: 
Firstly, it will be useful to further improve the ratio between TuD and sense strand 
expression levels, which can be achieved in numerous ways. For instance, the 
shRNA could be transcribed from an even weaker promoter which likely would 
not severely compromise shRNA efficiency but could improve the ratio between 
TuD and sense strand expression levels. Such a promoter could be an 
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attenuated version of H1 as described in a report on the functional 
characterization of this promoter (Hannon et al., 1991). Alternatively or in 
addition, the TuD can be placed under the control of a very potent promoter such 
as U6 as used in this study. An alternative way of attenuating sense strand levels 
relative to TuD levels without exchanging promoters could be to embed the 
shRNA within a miRNA scaffold (Zeng and Cullen, 2003b). This structure 
requires an additional processing step by Drosha and leads to lower intracellular 
levels of mature shRNA strands as compared to classical shRNAs of the same 
sequence (Boudreau et al., 2008). Potentially decreased efficiency of intended 
target silencing could be outweighed by increased specificity via more potent 
sense strand inactivation. The usefulness of this latter strategy is currently 
experimentally addressed in our lab on the example of shHBVS122. 
Secondly, in potential therapeutic applications inducible expression is absolutely 
necessary given the potential adverse side effects associated with high shRNA 
abundance. We therefore envision a future optimized variant of our system to 
express shRNAs expressed from an H1 and TuD from a U6 promoter that are 
both doxycycline-responsive as previously described (Aagaard et al., 2007). This 
would allow tight co-regulation of expression of both molecules. Pilot experiments 
for inducible TuD expression are currently ongoing in our lab. 
4.1.5 HCV inhibition by RNAi 
It has been shown that in the case of rapidly evolving viruses it is necessary to 
take measures to avoid viral mutational escape from therapy. One such measure 
is to target conserved sequences that are less prone to sequence modifications 
as done for the shRNA that shHCV318 is based on (Krönke et al., 2004). In 
addition, it is also helpful to use more than one shRNA which likewise makes viral 
escape from therapy less likely (Grimm and Kay, 2007b). Alternatively, RNAi can 
be combined with therapeutic measures that are based on different molecular 
principles (Anderson et al., 2007). In the case of HCV it has recently been 
demonstrated that miR-122-5p enhances HCV replication and antiviral treatment 
based on inhibition of this miRNA has already shown promising results (Jopling, 
2008; Lanford et al., 2010). miR-122-5p counteraction could hence be a good 
complementation to RNAi-mediated HCV inhibition. Our rAAV-based TuD 
expression strategy could be well suited for this approach especially since our lab 
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also possesses an AAV capsid variant with improved in vivo liver tropism (Grimm 
et al., 2008). Indeed, our preliminary data on inhibition of replication of HCV 
replicons provide a promising proof-of-concept. Our next step therefore is to 
combine shRNA and TuD in one single rAAV vector cooperatively expressing 
shHCV318 and a chimeric TuD that counteracts the shRNA sense strand and 
miR-122-5p at the same time. This combination of miR-122-5p inhibition and 
shHCV318 antisense activity should improve the efficiency of HCV treatment and 
at the same time decrease off-targeting from the shRNA sense strand merely by 
co-expressing two small RNA molecules (shRNA and TuD).  
We also use HCV as a model for this novel concept but it generally demonstrates 
that the possibilities of our system go beyond shRNA sense strand counteraction 
although this was the primary goal of our study. Additional applications for single 
vectors co-expressing an shRNA and a miRNA inhibitor include treatment of 
cancer and HIV as well as basic research related-questions. In some cancers 
miRNAs can act as antiapoptotic factors, such as miR-21-5p in glioblastoma 
(Chan et al., 2005). Co-inhibition of miR-21-5p by a TuD and an essential 
oncogene like c-myc by an shRNA might yield an additive effect (Wang et al., 
2008). During HIV infection, viral latency in resting CD4+ T-lymphocytes was 
linked to the activity of certain miRNAs, e.g. miR-125b-5p (Huang et al., 2007). 
HIV reservoirs might therefore be purged by inhibition of miR-125b-5p and 
concomitant shRNA-mediated degradation of newly produced HIV mRNAs; this 
strategy will in fact be tested in our laboratory using the vectors developed in this 
study.  
Successful shHCV318 sense strand counteraction was also interesting from a 
more biological point of view. HCV is a RNA (+) virus that produces a (-) strand 
as replication intermediate. While RNAi triggers are usually directed against the 
(+) strand genome it would be therapeutically useful to also target and destroy 
the (-) strand (Krönke et al., 2004; Wilson et al. 2005). Yet, a previous study in 
which sequences in the HCV 5’ UTR or NS5B were targeted with siRNAs 
suggested that the (-) strand is potentially immune to RNAi (Smith et al., 2007). 
This lack of (-) strand targeting could have two reasons: On the one hand, the (-) 
strand probably folds into a completely different 3D structure than the (+) strand. 
The target sites of the siRNAs could thus be accessible in the (+) but not the (-) 
strand. On the other hand, the (-) strand could be completely inaccessible to 
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RNAi triggers due to its intracellular localization. This hypothesis would be 
supported by the fact that the HCV (-) strand is associated with a virus-induced 
membranous microenvironment that could exclude certain cellular factors -
including RISC- and thus protect the strand against degradation (Herker and Ott, 
2011).  
The fact that inhibition of HCV replication was not altered by reducing sense 
strand activity via TuD co-expression indicated that HCV knockdown was entirely 
mediated by the shHCV318 antisense strand. We hence conclude that the HCV 
(-) strand was not targeted by our shRNA despite its high sense strand activity as 
measured by reporter assays. Our experimental setup thus provided a novel way 
of addressing the interactions between an RNAi trigger and HCV and confirmed 
the unique character of the HCV (-) strand. 
 
4.2 Processing and functionality of 5’ and 3’ strands 
While surprising at first, our finding that short shRNAs have the same Dicer 
requirements as longer versions does not necessarily disagree with previous in 
vitro data showing Dicer cleavage only in the case of a 25-mer shRNA but not a 
19-mer shRNA (Siolas et al., 2004). The discrepancy could be the reflection of 
experimental differences between in vitro assays and cell-based assays. Given 
that Dicer cuts the precursor into 22-mer pieces it seems logical that a 19-mer 
stem could be a worse substrate than a 25-mer stem. In the in vitro assays the 
shRNA substrates are incubated with purified Dicer for 2h which might then allow 
visualization of processing products of the 25-mer but not the 19-mer. However, 
this does not mean that the 19-mer is not processed at all. Instead, it is possible 
that upon expression in cells a low processing rate still yields functional levels of 
mature 3’ strands in the steady-state. If in our case hAAT19 really was no Dicer 
substrate at all we would not expect to observe any mature 3’ strands. Yet, we do 
observe a 3’ product but in agreement with lower processing rates at much lower 
levels than observed for the longer hAAT25 shRNA (cf. Fig.1E). 19-mer shRNAs 
thus seem to be processed by Dicer but are worse substrates than ≥21-mer 
shRNAs. Our findings demonstrate that while in vitro experiments may provide 
important insights into cellular processes they do not necessarily reflect the exact 
situation in living cells. 
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It was briefly discussed in the introduction (section 1.1.7.2) whether Dicer 
processing per se may lead to a strand bias or whether the key determinant is the 
thermodynamic asymmetry of the duplex. The results presented in this study 
support both views. We observed a bias towards the 3’ strand for all shRNAs that 
are supposedly good Dicer substrates, i.e. those with stem lengths of 21nt or 
longer. This finding along with the different Dicer dependencies of the two strands 
strongly implies that Dicer binding and/or processing per se indeed leads to 
preferential incorporation of the 3’ strand into RISC. However, we also saw 
drastic differences between different shRNAs in the degree of that strand bias 
implying that there are other parameters to take into account that are linked to the 
sequence of the respective RNAi trigger. In the case of shRNAs with perfect or 
almost perfect matched stems a combination of Dicer processing and sequence 
features such as thermodynamic asymmetry therefore seems to drive selection of 
the strands. 
It is noteworthy that the different Dicer dependencies of the two shRNA strands 
match recent observations by other groups on the Dicer-independent processing 
of a particular miRNA -i.e. miR-451- which upon review we found to have striking 
similarities to the shRNAs used here (Cheloufi et al., 2010; Cifuentes et al., 2010; 
Yang et al., 2010a). More precisely, the structure of pre-miR-451 resembles an 
18-mer stem shRNA. It expresses its 5’ strand by a Dicer-independent but Ago2 
slicing-dependent mechanism. This involves binding of Ago2 to the 5’ end of the 
shRNA, subsequent cleavage of the 3’ strand and resection to a size of 22-23nt. 
Our data suggest that this maturation process is not unique to miR-451 but, 
instead, is natural for all hairpin RNA molecules with perfectly matched stems, at 
least with stem lengths between 19 and 25nt. 
While the 3’ strands of all four shRNAs were non-functional in MEF Dicer-/- cells 
we observed a concomitant highly significant increase of 5’ strand activity with 
hAAT19 and a mildly significant increase with hAAT21. This augmented 5’ strand 
potency was also observed independently by another group that used the 
structure of miR-451 to design artificial hairpin molecules (Yang et al., 2010a). 
While in WT cells the 5’ strands of most of their constructs only had low silencing 
potentials the situation was dramatically different in Dicer-/- cells. Based on this 
and our own data we propose that Dicer binding might inhibit the non-canonical 5’ 
strand activation mechanism possibly by sterically hindering Ago2 binding. This 
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could even be part of the mechanism by which Dicer introduces the strand bias 
towards the 3’ strand. Interestingly, the enhanced potency of the 5’ strand is only 
observed for the shorter shRNAs but not the 23- and 25-mer versions. Altogether, 
these findings indicate that Dicer exerts a very complex role in modulating the 
activity of the 5‘ strand whose further elucidation will be an important and exciting 
goal for future studies. 
Notably, we were able to associate the difference in Dicer requirement with 
unique behavior of the two shRNA strands. Our hallmark finding was that the 5’ 
strand could be counteracted by an inhibitor molecule whereas the 3’ strand was 
principally inert. This novel and unanticipated observation suggests that the 
shRNA maturation processes yield functionally distinct strands. Interestingly, prior 
biochemical data indicate that RISC is relatively flexible and interacts with many 
different cellular factors (Meister et al., 2005; Landthaler et al., 2008) in turn 
implying that RISC composition varies according to e.g. cell types, cellular stress 
states or target mRNAs. A tempting ensuing hypothesis is that the composition of 
RISC may also differ between the 5’ and the 3’ strand of an shRNA, which could 
readily explain the functional peculiarities observed in this study. If true, this 
exciting new finding would fundamentally modify and expand our current 
understanding of cellular processes for small RNA maturation and activity, and 
thus have broad implications for future basic and applied RNAi research. 
Fortunately, the present work has not only paved the way for this potential 
important biological discovery, but has concurrently also already provided the 
experimental tools and strategies for its further dissection as well as, ideally, for 
its looming biomedical translation. 
DISCUSSION 
______________________________________________________________________________ 
5 CONCLUSION 
In this study, we demonstrate that undesired sense strand activity can have a 
greater impact on the specificity of an shRNA than generally believed (see Fig. 
24 for graphical summary of results). We have generated bi-functional rAAV 
vectors that express an shRNA along with an inhibitor RNA. Our vector design 
allows counteraction of undesired sense strand activity upon shRNA expression 
and thereby reduction of off-target effects. As improving specificity is a major 
concern in the design of exogenous RNAi triggers, we are convinced that our 
novel sequestration-based method holds marked potential to be applied in the 
future design of shRNA-based silencing strategies. In addition, we envision the 
use of our bi-functional vectors in biomedical applications in which shRNA-
mediated silencing should be combined with inhibition of specific miRNAs. 
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Fig. 24: Summary of results. We have generated bi-functional self -complementary rAAV
vectors for the expression of both an shRNA and an inhibitor RNA molecule. A: The shRNA
should be designed with the antisense strand at the 3‘ end and a stem of 21nt or more. Despite
this design, the shRNA sense strand can be highly active and produce off -target effects. B:
Co-expression of a TuD directed against the shRNA sense strand can counteract its activity
and thereby partially relieve off -targeting. This approach requires that TuD expression is
considerably more potent than shRNA expression. C: One binding site is sufficient for maximal
TuD activity. TuDs can thus be generated with bindings sites for two different triggers of RNAi
which can be useful in a variety of different applications. D: TuD binding sites are best
designed with perfect complementarity to the RNAi trigger. Alteratively, high aff inity sites with
single mismatches at position 10 or 11 can be used.
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6 SUPPLEMENTARY MATERIAL 
 
6.1 Supplementary data 
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Suppl.Fig. 1: Analysis of 3‘ and 5' strand activities for the shRNAs sAg19 and sAg25.
A+B: HEK293T cells were transfected with indicated amounts of U6-sAg19 (A) or sAg25 (B)
and strand activities were determined at 48h post-transfection. Numbers indicate the RSAs at
the respective concentrations. RSA=relative strand activity.
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shRNAs  
Name  Sequence (5‘?3‘, 5’arm-loop-3’ arm, antisense strand underlined, loop in italics) 
sAg19 GAACAAATGGCACTAGTAA TCAAGAG TTACTAGTGCCATTTGTTC 
sAg25 GAACAAATGGCACTAGTAAACTGAG TCAAGAG CTCAGTTTACTAGTGCCATTTGTTC 
sAg21SA GTTTACTAGTGCCATTTGTTC TCAAGAG GAACAAATGGCACTAGTAAAC 
hAAT19 GAAGCGTTTAGGCATGTTT TCAAGAG AAACATGCCTAAACGCTTC 
hAAT21 GAAGCGTTTAGGCATGTTTAA TCAAGAG TTAAACATGCCTAAACGCTTC 
hAAT23 GAAGCGTTTAGGCATGTTTAACA TCAAGAG TGTTAAACATGCCTAAACGCTTC 
hAAT25 GAAGCGTTTAGGCATGTTTAACATC TCAAGAG GATGTTAAACATGCCTAAACGCTTC 
hAAT25R GATGTTAAACATGCCTAAACGCTTC TCAAGAG GAAGCGTTTAGGCATGTTTAACATC 
shHBVS1 GGTATGTTGCCCGTTTGTCT TCAAGAG AGACAAACGGGCAACATACC 
shHBVS122 GGTATGTTGCCCGTTTGTCTTC TCAAGAG GAAGACAAACGGGCAACATACC 
shHCV318 GGGAGGTCTCGTAGACCGTGCA TCAAGAG TGCACGGTCTACGAGACCTCCC 
shP53P7 GGAGCTGAATGAGGCCTTAGA TCAAGAG TCTAAGGCCTCATTCAGCTCC 
sh122SA TGGAGTGTGACAATGGTGTTTGT CCTGACCCA ACAAACACCATTGTCACACTCCA 
sh122AS ACAAACACCATTGTCACACTCCA CCTGACCCA TGGAGTGTGACAATGGTGTTTGT 
 
Binding sites in Rluc or d2eGFP 3’ UTRs  
Name Sequence (5‘?3‘) 
hAAT „Intended“ (=3’ strand target for hAAT19-25 and 5’ strand 
target for hAAT25R in Fig. 1) 
GAAGCGTTTAGGCATGTTTAACATC 
hAAT „Unintended perfect“ (=5’ target strand for hAAT19-25 and 
3’ strand target for hAAT25R in Fig. 1) 
GATGTTAAACATGCCTAAACGCTTC 
hAAT „Unintended imperfect“ GATGTTAAACATGCTTAAACGCTTC 
HCV318 „Intended“ (=3’ strand target in Fig. 1) GGGAGGTCTCGTAGACCGTGCA 
HCV318 „Unintended perfect“ (=5’ strand target in Fig. 1) TGCACGGTCTACGAGACCTCCC 
HCV318 „Unintended imperfect“ TGCACGGTCTATGAGACCTCCC 
HBVS1 „Intended“ (=3’ strand target in Fig. 1) GGTATGTTGCCCGTTTGTCT 
HBVS1 „Unintended perfect“ (=5’ strand target in Fig. 1) AGACAAACGGGCAACATACC 
sAg 3’ strand target (Fig.1 and Suppl.Fig. 1) CTCAGTTTACTAGTGCCATTTGTTC 
sAg 5’ strand target (Fig.1 and Suppl.Fig. 1) GAACAAATGGCACTAGTAAACTGAG 
P53P7 3’ strand target (Fig.1) GGAGCTGAATGAGGCCTTAGA 
P53P7 5’ strand target (Fig.1) TCTAAGGCCTCATTCAGCTCC 
sh122SA 3’ strand target (Fig.1) TGGAGTGTGACAATGGTGTTTGT 
sh122SA 5’ strand target (Fig.1) ACAAACACCATTGTCACACTCCA 
sh122AS 3’ strand target (Fig.1) ACAAACACCATTGTCACACTCCA 
sh122AS 5’ strand target (Fig.1) TGGAGTGTGACAATGGTGTTTGT 
Random target for hAAT sense strand GATGTTAAACATG NNN AAACGCTTC 
miR-122-5p imperfect site, Fig. 23 ACAAACACCATGCCAACACTCCA 
 
TuD binding sites  
Name (bs1/bs2; i=imperfect, 
p=perfect, u=unspecific) 
Sequence (5‘?3‘, bs1-stem loop-bs2, stem loop in italics) 
TuD-HCV318 for sense 
strand (u/i) 
AGCACGATAAATGAGACCTCCC CAAGTATTCTGGTCACAGAATACAAC 
TGCACGGTCTATGAGACCTCCC 
TuD-hAAT for sense strand 
(i/i) 
TTAAACATGCATAAACGCTTC CAAGTATTCTGGTCACAGAATACAAC 
TTAAACATGCCGAAACGCTTC 
TuD-HBVS1 for sense strand 
(i/i) 
AGACAAACGTGCAACATACC CAAGTATTCTGGTCACAGAATACAAC 
AGACAAACGAGCAACATACC 
TuD-hAAT for sense strand 
(p/p) 
TTAAACATGCCTAAACGCTTC CAAGTATTCTGGTCACAGAATACAAC 
GTTAAACATGCCTAAACGCTTC 
TuD-hAAT for antisense 
strand (p/u) 
AGCGTTTAGGCATGTTTAACAT CAAGTATTCTGGTCACAGAATACAAC 
TGCACGGTCTATGAGACCTCCC 
Chimeric TuD-hAAT/HCV318 
for sense strands (p/p) 
TTAAACATGCCTAAACGCTTC CAAGTATTCTGGTCACAGAATACAAC 
TGCACGGTCTACGAGACCTCCC 
TuD-miR-122-5p (i/i) CAAACACCATGCCAACACTCCA CAAGTATTCTGGTCACAGAATACAAC 
CAAACACCATGCCAACACTCCA 
 
Suppl.Tab. 1: Sequences of shRNAs, 3’ UTR targets and TuDs used in this study.  
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Suppl.Fig. 2: Fluorescence reporter knockdown analysis by FACS. A: For setup of the
gating strategy and adjustment of compensation settings, HEK293T cells were either lef t naïve
or transfected with an mCherry or eGFP expression plasmid and analyzed by FACS 48h post-
transfection. Detector and compensation settings were adjusted so that naive cells were below
101 and no false positive cells appeared in the mCherry channel for eGFP only. B: For
measurement of mCherry and eGFP expression, HEK293T cells -either naive or transfected
with dual f luorescence and shRNA plasmids- were analyzed by FACS 48h post-transfection.
Viable cells were gated through R1. mCherry-positive cells were gated through R2. Mean
values for mCherry and eGFP expression in R2 were used for calculation of relative eGFP
expression. Shown are two exemplary samples of the knockdown analysis. shHCV318 with
control or specif ic TuD was transfected into HEK293T cells along with dual f luorescence
reporter plasmids. Grey bars indicate mean expression values.
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Suppl.Fig. 3: TuD expression by far exceeds
shRNA expression. Huh7 cells were transduced
(MOI=105) with rAAV2 encoding shRNA and TuD as
indicated. 48h post-transduction, total RNA was
extracted, and shRNA and TuD were detected by
Northern blot. Perfectly matched probes were used for
each molecule and contrast settings for TuD and
shRNA sense or antisense strand are similar. The
complex structure of the TuD can lead to the detection
of several bands despite denaturing running conditions
Haraguchi ., 09)
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Suppl.Fig. 4: miArray validation by qPCR. A: Total RNA was extracted from naive Huh7
cells or Huh7 cells transduced with rAAV2 (MOI=105) encoding shRNA and TuD as indicated.
Transcript levels of indicated genes were measured by RT-qPCR. Signif icance was
determined by unpaired, two-sided T-test (* p<0.05; ** p<0.005; *** p<0.0005). B: miArray
results for the same genes for comparison.
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Suppl.Fig. 5: Analysis of target dysregulation for other hepatic miRNAs. A-C: Relative
expression of validated target genes of miR-16-5p (A), miR-21-5p (B), miR-22-3p (C), miR-24-
3p (D), miR-130a-3p (E), and miR-192-5p (F), as determined by miArray were plotted. For
easy comparison to the data to Fig.15 the threshold used for off -target analysis previously is
shown as grey line. Black bars represent the mean values of each dataset.
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Suppl.Fig. 6: For some shRNAs H1-TuDs do not counteract sense strand upon rAAV2-
mediated transduction. A+B: Transfection of HEK293T cells with hAAT25 plus TuD and
luciferase targets for both strands (A) or transduction of Huh7 cells (MOI=105) with hAAT25
plus TuD and co-transfection with luciferase targets for both strands (B). Strand activities were
measured by dual luciferase assay 48h post-transfection. Statistical analysis: unpaired, two-
sided T-test, ** p<0.005, *** p<0.0005.
A B
0%
20%
40%
60%
80%
100%
RL
U
0%
20%
40%
60%
80%
100%
RL
U
***
H1-shRNA
Spec. 
H1-TuD +
- +
-
+
+
+
+
-
+
Unintended
„perfect“
Intended
H1-shRNA
Spec. 
H1-TuD +
- +
-
+
+
+
+
-
+
Unintended
„perfect“
Intended
 
 
6.2 Relevant weblinks 
microRNA database miRBase: www.mirbase.org 
Journal of Gene Medicine, information on gene therapy trials: 
http://www.abedia.com/wiley/vectors.php 
Biomart tool: www.biomart.org 
TarBase : http://diana.cslab.ece.ntua.gr/DianaToolsNew/index.php?r=tarbase/index 
Primer bank database: http://pga.mgh.harvard.edu/primerbank/ 
microRNA.org database: www.microRNA.org 
Centroid fold RNA folding prediction: www.ncrna.org/centroidfold 
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